id,conversation_id,created_at,date,time,timezone,user_id,username,name,place,tweet,language,mentions,urls,photos,replies_count,retweets_count,likes_count,hashtags,cashtags,link,retweet,quote_url,video,thumbnail,near,geo,source,user_rt_id,user_rt,retweet_id,reply_to,retweet_date,translate,trans_src,trans_dest
1205552193732001793,1205552193732001793,2019-12-13 23:46:55 IST,2019-12-13,23:46:55,+0530,234905402,halftimereport,CNBC Halftime Report,,Gilead Sciences downgraded to underperform at Credit Suisse.  The investment committee debates $GILD and the rest of the health care sector in our #CalloftheDay.  https://t.co/lDIrrxIqfh,en,[],[],[],4,2,15,['calloftheday'],['gild'],https://twitter.com/HalftimeReport/status/1205552193732001793,False,,1,https://pbs.twimg.com/media/ELr7U_MWwAAo6Ax.jpg,,,,,,,[],,,,
1205115306475167744,1205115306475167744,2019-12-12 18:50:53 IST,2019-12-12,18:50:53,+0530,873399943,jacobplieth,Jacob Plieth,,KTE-X19 = Yescarta with a different manufacturing process $GILD,en,[],[],[],5,6,18,[],['gild'],https://twitter.com/JacobPlieth/status/1205115306475167744,False,https://twitter.com/abhinav_deol/status/1204139288516018176,0,,,,,,,,[],,,,
1204872547197689857,1204872547197689857,2019-12-12 02:46:15 IST,2019-12-12,02:46:15,+0530,274233761,bradloncar,Brad Loncar,,$GILD Kite filed its BLA for mantle cell lymphoma. Potentially a new milestone for cell Tx indications.,en,[],[],[],1,9,17,[],['gild'],https://twitter.com/bradloncar/status/1204872547197689857,False,,0,,,,,,,,[],,,,
1203657541617684482,1203657541617684482,2019-12-08 18:18:15 IST,2019-12-08,18:18:15,+0530,873399943,jacobplieth,Jacob Plieth,,If you're invested in the $CELG CVR read my take on yesterday's Transcend-NHL data at #ASH19. Via @Vantageanalysis  https://t.co/gbjESFh3mv $BMY $GILD $NVS,en,"[{'screen_name': 'vantageanalysis', 'name': 'evaluate vantage', 'id': '3033767986'}]",['https://www.evaluate.com/vantage/articles/events/conferences/ash-2019-former-celgene-holders-look-anxiously-contingent-value'],[],2,12,37,['ash19'],"['celg', 'bmy', 'gild', 'nvs']",https://twitter.com/JacobPlieth/status/1203657541617684482,False,,0,,,,,,,,[],,,,
1203420849287630848,1203353015551451137,2019-12-08 02:37:43 IST,2019-12-08,02:37:43,+0530,873399943,jacobplieth,Jacob Plieth,,Quick &amp; dirty comparison of Yescarta vs Kymriah vs JCAR017 in lymphoma (because we all LOVE X-study comparisons!) #ASH19 $GILD $NVS $BMY  https://t.co/VVZtd4UztX,en,[],[],['https://pbs.twimg.com/media/ELNo4TiXkAAR2LP.jpg'],1,10,26,['ash19'],"['gild', 'nvs', 'bmy']",https://twitter.com/JacobPlieth/status/1203420849287630848,False,,1,https://pbs.twimg.com/media/ELNo4TiXkAAR2LP.jpg,,,,,,,[],,,,
1203353015551451137,1203353015551451137,2019-12-07 22:08:10 IST,2019-12-07,22:08:10,+0530,873399943,jacobplieth,Jacob Plieth,,"If you're looking forward to today's Transcend-NHL data with $BMY JCAR017 (2pm at #ASH19) you'll want to bear in mind OS &amp; PFS from $GILD Zuma-1 and $NVS Juliet studies, per #ASCO19  https://t.co/74aqIHpwmU",en,[],[],"['https://pbs.twimg.com/media/ELMrI38X0AE3RYT.jpg', 'https://pbs.twimg.com/media/ELMrLTpWkAEhZpX.jpg']",2,7,27,"['ash19', 'asco19']","['bmy', 'gild', 'nvs']",https://twitter.com/JacobPlieth/status/1203353015551451137,False,,1,https://pbs.twimg.com/media/ELMrI38X0AE3RYT.jpg,,,,,,,[],,,,
1202024019215757318,1202024019215757318,2019-12-04 06:07:13 IST,2019-12-04,06:07:13,+0530,44438256,matthewherper,Matthew Herper,,"The biggest drugs in the world are chronic: reclined, $GILD‚Äôs HIV drugs, Humira, @natesadeghi said. #STATPlusLive",en,"[{'screen_name': 'natesadeghi', 'name': 'nathan sadeghi-nejad', 'id': '56486495'}]",[],[],3,1,11,['statpluslive'],[],https://twitter.com/matthewherper/status/1202024019215757318,False,,0,,,,,,,,[],,,,
1197605801613053954,1197605801613053954,2019-11-22 01:30:48 IST,2019-11-22,01:30:48,+0530,368158573,rebeccadrobbins,Rebecca Robbins,,Here are some highlights from this week's #STATsummit: Machine learning experts:  https://t.co/p34oDNALH5 $BLUE CEO:  https://t.co/4rM22QR4ZY Jim Wilson:  https://t.co/LnZBxm26bL $GILD CEO:  https://t.co/3cUR7fouDY Charles Sawyers:  https://t.co/bLgGSt5CvS,en,[],"['https://www.statnews.com/2019/11/21/machine-learning-will-yield-new-drug-candidates-within-three-years/', 'https://www.statnews.com/2019/11/21/biotech-ceos-own-up-to-bad-reputation/', 'https://www.statnews.com/2019/11/21/gene-therapy-pioneer-says-the-field-is-behind-and-that-delivery-technology-is-embarrassing/', 'https://www.statnews.com/2019/11/20/gilead-ceo-daniel-oday-says-company-is-in-an-acquisitive-mode/', 'https://www.statnews.com/2019/11/21/charles-sawyers-cancer-stat-biomedical-innovation-award-winner/']",[],0,2,7,['statsummit'],"['blue', 'gild']",https://twitter.com/RebeccaDRobbins/status/1197605801613053954,False,,0,,,,,,,,[],,,,
1197303294898692103,1197303294898692103,2019-11-21 05:28:44 IST,2019-11-21,05:28:44,+0530,44438256,matthewherper,Matthew Herper,,O‚ÄôDay in his move: How many companies have cured a disease and turned another into a chronic one? #STATSummit $gild,en,[],[],[],2,1,19,['statsummit'],['gild'],https://twitter.com/matthewherper/status/1197303294898692103,False,,0,,,,,,,,[],,,,
1192476204084973569,875004688369954816,2019-11-07 21:47:36 IST,2019-11-07,21:47:36,+0530,873399943,jacobplieth,Jacob Plieth,,~8% manufacturing failure rate for JCAR017 seems broadly in line with those Kymriah data from 2017 cc @cells_nnm $CELG $NVS $GILD #ASH19  https://t.co/enzWhmpZgH,en,"[{'screen_name': 'cells_nnm', 'name': 'alexey bersenev', 'id': '14063950'}]",[],['https://pbs.twimg.com/media/EIyGvb9WoAIyyoY.jpg'],1,4,11,['ash19'],"['celg', 'nvs', 'gild']",https://twitter.com/JacobPlieth/status/1192476204084973569,False,,1,https://pbs.twimg.com/media/EIyGvb9WoAIyyoY.jpg,,,,,,,[],,,,
1187488941848584192,1187488941848584192,2019-10-25 03:30:00 IST,2019-10-25,03:30:00,+0530,47678782,megtirrell,Meg Tirrell,,With some üî•üî•üî• coming from @BrianSkorney on $GILD,en,"[{'screen_name': 'brianskorney', 'name': 'brian skorney', 'id': '285598594'}]",[],[],2,3,15,[],['gild'],https://twitter.com/megtirrell/status/1187488941848584192,False,https://twitter.com/CNBCFastMoney/status/1187480714134118406,0,,,,,,,,[],,,,
1187480714134118406,1187480714134118406,2019-10-25 02:57:19 IST,2019-10-25,02:57:19,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,Gilead getting a bad prognosis from Wall Street as the stock falls after earnings. @megtirrell shares what could be weighing on the stock. $GILD  https://t.co/pvTcls505r,en,"[{'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}]",[],[],1,6,13,[],['gild'],https://twitter.com/CNBCFastMoney/status/1187480714134118406,False,,1,https://pbs.twimg.com/media/EHrHac9WwAAbMHw.jpg,,,,,,,[],,,,
1187465813202231296,1187465288389971968,2019-10-25 01:58:06 IST,2019-10-25,01:58:06,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"@sharkbiotech Maybe it‚Äôs just the insanely business week and I‚Äôm really tired, but I didn‚Äôt even bother to peek at $GILD earnings release. I figured, unless I see on Twitter that Gilead filed for bankruptcy, I can wait to read an analyst report tomorrow.",en,[],[],[],2,0,10,[],['gild'],https://twitter.com/adamfeuerstein/status/1187465813202231296,False,,0,,,,,,,,"[{'screen_name': 'sharkbiotech', 'name': 'Dan Rosenblum', 'id': '255996385'}]",,,,
1187462025196298242,1187462025196298242,2019-10-25 01:43:03 IST,2019-10-25,01:43:03,+0530,274233761,bradloncar,Brad Loncar,,$GILD Q3 Yescarta sales were sequentially down compared to Q2.  https://t.co/fHPcituivT  https://t.co/MxrnwflJrH,en,[],['http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-third-quarter-2019-financial-results'],['https://pbs.twimg.com/media/EHq2YtsWwAA3N0q.jpg'],8,7,27,[],['gild'],https://twitter.com/bradloncar/status/1187462025196298242,False,,1,https://pbs.twimg.com/media/EHq2YtsWwAA3N0q.jpg,,,,,,,[],,,,
1187410671199313920,1187410671199313920,2019-10-24 22:18:59 IST,2019-10-24,22:18:59,+0530,47678782,megtirrell,Meg Tirrell,,This is great. $GILD,en,[],[],[],3,3,19,[],['gild'],https://twitter.com/megtirrell/status/1187410671199313920,False,https://twitter.com/NedPagliarulo/status/1187353804678848512,0,,,,,,,,[],,,,
1186788273458503680,1186788273458503680,2019-10-23 05:05:48 IST,2019-10-23,05:05:48,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Today was‚Ä¶ sorta busy, so I‚Äôm only now reading this üò≥üëèüí•üéñüíØüî•üî•üî• profile of Trump healthcare policy aide Joe Grogan written by @levfacher. (Grogan is a former $GILD lobbyist.) Superb reporting right here:   https://t.co/3W6t93SR1t",en,"[{'screen_name': 'levfacher', 'name': 'lev facher', 'id': '28454841'}]",['https://www.statnews.com/2019/10/22/joe-grogan-upended-trump-drug-pricing-agenda/'],[],0,3,13,[],['gild'],https://twitter.com/adamfeuerstein/status/1186788273458503680,False,,0,,,,,,,,[],,,,
1186291045903896577,1186291045903896577,2019-10-21 20:10:00 IST,2019-10-21,20:10:00,+0530,274233761,bradloncar,Brad Loncar,,Healthcare earnings coming up this week:  T: $BIIB $NVS W: $ALXN $ALKS $BMRN $LLY T: $AZN $BAX $GILD $ILMN F: $GLPG  Full schedule:  https://t.co/kSMQD3viun  https://t.co/gHQN1nxAEa,en,[],['https://www.loncarblog.com/october-21-earnings'],['https://pbs.twimg.com/media/EHW9ci1WwAAMBlv.jpg'],0,6,18,[],"['biib', 'nvs', 'alxn', 'alks', 'bmrn', 'lly', 'azn', 'bax', 'gild', 'ilmn', 'glpg']",https://twitter.com/bradloncar/status/1186291045903896577,False,,1,https://pbs.twimg.com/media/EHW9ci1WwAAMBlv.jpg,,,,,,,[],,,,
1184140660917620744,1184140660917620744,2019-10-15 21:45:08 IST,2019-10-15,21:45:08,+0530,3043828834,cgrantwsj,Charley Grant,,Advice from buyside survey for new $GILD CFO Andrew Dickinson in a Mizuho note. This one is particularly helpful:  https://t.co/JNkOCL7Trh,en,[],[],['https://pbs.twimg.com/media/EG7pp6gWoAA-hRA.png'],2,3,23,[],['gild'],https://twitter.com/CGrantWSJ/status/1184140660917620744,False,,1,https://pbs.twimg.com/media/EG7pp6gWoAA-hRA.png,,,,,,,[],,,,
1181187025980014592,1181187025980014592,2019-10-07 18:08:27 IST,2019-10-07,18:08:27,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$GILD has a new chief medical officer.    https://t.co/ZOqWLcdhVr,en,[],['http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-appoints-merdad-parsey-md-phd-chief-medica'],[],3,1,10,[],['gild'],https://twitter.com/adamfeuerstein/status/1181187025980014592,False,,0,,,,,,,,[],,,,
1179830979751374848,1179830979751374848,2019-10-04 00:20:00 IST,2019-10-04,00:20:00,+0530,47678782,megtirrell,Meg Tirrell,,FDA approves $GILD's Descovy as new version of PrEP (HIV pre-exposure prophylaxis); excludes cisgender women due to lack of studies in that population:  https://t.co/TaGLAHZe58,en,[],['https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic'],[],0,7,17,[],['gild'],https://twitter.com/megtirrell/status/1179830979751374848,False,,0,,,,,,,,[],,,,
1178708344124653573,1178708344124653573,2019-09-30 21:59:03 IST,2019-09-30,21:59:03,+0530,19546277,yahoofinance,Yahoo Finance,,Highlight: @ArielInvests CIO Rupal Bhansali on why MANG is better than FANG. MANG stands for $MGDDY $DOX $NOK $GILD:  https://t.co/HYC8rBqm1M,en,"[{'screen_name': 'arielinvests', 'name': 'ariel investments', 'id': '612574787'}]",[],[],3,6,42,[],"['mgddy', 'dox', 'nok', 'gild']",https://twitter.com/YahooFinance/status/1178708344124653573,False,,1,https://pbs.twimg.com/media/EFuclWGWoAAtY15.jpg,,,,,,,[],,,,
1177294973961678849,1177294973961678849,2019-09-27 00:22:49 IST,2019-09-27,00:22:49,+0530,234905402,halftimereport,CNBC Halftime Report,,"Marathon Petroleum's rise ""ain't done,"" says @jlebenthal, while @terranovajoe believes Adobe is ""one of the best companies out there"" from a fundamental perspective.  Plus: why Brenda Vingiello is buying $GILD, and @petenajarian's trade on $LOW  https://t.co/J23WYOZVEk",en,"[{'screen_name': 'jlebenthal', 'name': 'jim lebenthal', 'id': '54903435'}, {'screen_name': 'terranovajoe', 'name': 'joe terranova', 'id': '28445389'}, {'screen_name': 'petenajarian', 'name': 'pete najarian', 'id': '14292717'}]",[],[],2,5,9,[],"['gild', 'low']",https://twitter.com/HalftimeReport/status/1177294973961678849,False,,1,https://pbs.twimg.com/media/EFaXiW6XoAEYBrC.jpg,,,,,,,[],,,,
1159188900453240832,1159188900453240832,2019-08-08 01:15:45 IST,2019-08-08,01:15:45,+0530,47678782,megtirrell,Meg Tirrell,,"FDA advisory committee vote on $GILD Descovy for PrEP Question 1  Yes: 16 No: 2  (Note: FDA doesn't have to follow advisory committee's advice, but often does. Agency expected to decide on drug by October)",en,[],[],[],1,3,7,[],['gild'],https://twitter.com/megtirrell/status/1159188900453240832,False,https://twitter.com/megtirrell/status/1159186428749864960,0,,,,,,,,[],,,,
1159074000032735238,1159074000032735238,2019-08-07 17:39:10 IST,2019-08-07,17:39:10,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Former $GILD CSO John McHutchison is new $ASMB CEO.,en,[],[],[],0,2,15,[],"['gild', 'asmb']",https://twitter.com/adamfeuerstein/status/1159074000032735238,False,https://twitter.com/BrianSkorney/status/1159073012588666880,0,,,,,,,,[],,,,
1156295719315226629,1156295719315226629,2019-07-31 01:39:17 IST,2019-07-31,01:39:17,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$GILD w/ BIG Biktarvy HIV sales for Q2: $1.1B,en,[],[],[],0,1,16,[],['gild'],https://twitter.com/adamfeuerstein/status/1156295719315226629,False,,0,,,,,,,,[],,,,
1156293176665280517,1156293176665280517,2019-07-31 01:29:10 IST,2019-07-31,01:29:10,+0530,274233761,bradloncar,Brad Loncar,,$GILD FactSet consensus for Yescarta sales tonight is around $113M.,en,[],[],[],1,0,7,[],['gild'],https://twitter.com/bradloncar/status/1156293176665280517,False,,0,,,,,,,,[],,,,
1156292749236289538,1156292749236289538,2019-07-31 01:27:28 IST,2019-07-31,01:27:28,+0530,21778391,cnbcclosingbell,CNBC's Closing Bell,,STILL TO COME AFTER THE BELL: Earnings from $AAPL $AMGN $GILD $MDLZ $EA $YUMC $FEYE $GPRN $HA  https://t.co/OfPWKeXS1e,en,[],[],"['https://pbs.twimg.com/media/EAv58vGXYAENcp-.jpg', 'https://pbs.twimg.com/media/EAv59H_WkAAIl1H.jpg']",1,8,9,[],"['aapl', 'amgn', 'gild', 'mdlz', 'ea', 'yumc', 'feye', 'gprn', 'ha']",https://twitter.com/CNBCClosingBell/status/1156292749236289538,False,,1,https://pbs.twimg.com/media/EAv58vGXYAENcp-.jpg,,,,,,,[],,,,
1156198765671387137,1156198765671387137,2019-07-30 19:14:01 IST,2019-07-30,19:14:01,+0530,14886375,stocktwits,Stocktwits,,"Ladies and gentlemen, get ready for today‚Äôs earnings. There‚Äôs one company everyone will be watching:  $AAPL üëÄ $AMD $GILD $EA $GRPN (yes, Groupon is still alive) $FEYE $AMGN   https://t.co/Dpd0nIvHiy",en,[],['http://stocktwits.com/symbol/AAPL'],[],2,9,19,[],"['aapl', 'amd', 'gild', 'ea', 'grpn', 'feye', 'amgn']",https://twitter.com/Stocktwits/status/1156198765671387137,False,,0,,,,,,,,[],,,,
1155836733931626496,1155836733931626496,2019-07-29 19:15:26 IST,2019-07-29,19:15:26,+0530,14886375,stocktwits,Stocktwits,,Earnings this week    Mon - $BYND $AKS $ILMN  Tue - $AAPL $AMD $GILD $EA $PFE $MA $PG $MO  Wed - $GE $FIT $QCOM $AMRN  Thu - $SQ $GPRO $SHOP  Fri - $XOM $CVX     https://t.co/BrJnctSA18,en,[],['https://stocktwits.com/discover/earnings-calendar'],[],0,7,20,[],"['bynd', 'aks', 'ilmn', 'aapl', 'amd', 'gild', 'ea', 'pfe', 'ma', 'pg', 'mo', 'ge', 'fit', 'qcom', 'amrn', 'sq', 'gpro', 'shop', 'xom', 'cvx']",https://twitter.com/Stocktwits/status/1155836733931626496,False,,0,,,,,,,,[],,,,
1155540171229728769,1155540171229728769,2019-07-28 23:37:00 IST,2019-07-28,23:37:00,+0530,274233761,bradloncar,Brad Loncar,,Big week of earnings ahead.  M: $ILMN $NBIX $SNY T: $AMGN $GILD $INCY $MRK $PFE W: $ACAD $AMRN $EXEL $VRTX T: $BPMC $CLVS $IOVA $VKTX F: $IMGN  Full list here:  https://t.co/rkVR6KO4b7  https://t.co/fM7N4kAQLg,en,[],['https://www.loncarblog.com/july-29-earnings'],['https://pbs.twimg.com/media/EAgoy8DUYAAqfOB.jpg'],0,18,40,[],"['ilmn', 'nbix', 'sny', 'amgn', 'gild', 'incy', 'mrk', 'pfe', 'acad', 'amrn', 'exel', 'vrtx', 'bpmc', 'clvs', 'iova', 'vktx', 'imgn']",https://twitter.com/bradloncar/status/1155540171229728769,False,,1,https://pbs.twimg.com/media/EAgoy8DUYAAqfOB.jpg,,,,,,,[],,,,
1153683099848515585,1153683099848515585,2019-07-23 20:37:40 IST,2019-07-23,20:37:40,+0530,44438256,matthewherper,Matthew Herper,,"""If you would have told me even a few years ago that you could find a molecule [like this], I would have never ever believed it.‚Äù   $MRK begins unveiling new HIV drug. $GILD $GSK   https://t.co/QdB2oYtxMo",en,[],['https://www.statnews.com/2019/07/23/merck-unveils-early-data-on-hiv-drug-it-says-could-be-a-game-changer/'],[],0,22,47,[],"['mrk', 'gild', 'gsk']",https://twitter.com/matthewherper/status/1153683099848515585,False,,0,,,,,,,,[],,,,
1151937518436175872,1151937518436175872,2019-07-19 01:01:21 IST,2019-07-19,01:01:21,+0530,368158573,rebeccadrobbins,Rebecca Robbins,,".@statnews' latest podcast episode just posted. We discuss: üîπ Neuralink, ft. clips from Elon Musk's presentation üîπ $GILD üîπdesigning mental health apps, ft. @meggophone  üîπ $VNDA &amp; vomit on a boat üîπ Grimes' Instagram post  https://t.co/gPUzDtAIet",en,"[{'screen_name': 'statnews', 'name': 'stat', 'id': '3290364847'}, {'screen_name': 'meggophone', 'name': 'megan thielking', 'id': '418934617'}]",['https://www.statnews.com/2019/07/18/elon-musks-monkey-cyborg-gileads-shifting-future-an-app-for-anxiety/'],[],0,7,13,[],"['gild', 'vnda']",https://twitter.com/RebeccaDRobbins/status/1151937518436175872,False,,0,,,,,,,,[],,,,
1150743523135827968,1150743523135827968,2019-07-15 17:56:50 IST,2019-07-15,17:56:50,+0530,47678782,megtirrell,Meg Tirrell,,"Coming up on @SquawkCNBC: $GILD CEO Dan O‚ÄôDay. We‚Äôll talk $GLPG deal, future strategy and more. Tune in",en,"[{'screen_name': 'squawkcnbc', 'name': 'squawk box', 'id': '404422077'}]",[],[],1,4,17,[],"['gild', 'glpg']",https://twitter.com/megtirrell/status/1150743523135827968,False,,0,,,,,,,,[],,,,
1150733095169122305,1150733095169122305,2019-07-15 17:15:24 IST,2019-07-15,17:15:24,+0530,44438256,matthewherper,Matthew Herper,,"My interview w/ Dan---&gt; With $5 billion Galapagos deal, CEO Daniel O‚ÄôDay starts putting his stamp on Gilead  https://t.co/UovpYlBMWx $GILD",en,[],['https://www.statnews.com/2019/07/15/with-5-billion-galapagos-deal-ceo-oday-starts-putting-his-stamp-on-gilead/'],[],0,1,8,[],['gild'],https://twitter.com/matthewherper/status/1150733095169122305,False,,0,,,,,,,,[],,,,
1150708375480672257,1150708375480672257,2019-07-15 15:37:10 IST,2019-07-15,15:37:10,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Something happened between $GILD and $GLPG while I was away. @matthewherper spoke to $GILD CEO Dan O‚ÄôDay  ‚Äî&gt;  https://t.co/OJjH0bGity,en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.statnews.com/2019/07/15/with-5-billion-galapagos-deal-ceo-oday-starts-putting-his-stamp-on-gilead/'],[],2,5,9,[],"['gild', 'glpg', 'gild']",https://twitter.com/adamfeuerstein/status/1150708375480672257,False,,0,,,,,,,,[],,,,
1150502668164636672,1150502668164636672,2019-07-15 01:59:46 IST,2019-07-15,01:59:46,+0530,47678782,megtirrell,Meg Tirrell,,$GILD CEO Dan O‚ÄôDay joins us on @SquawkCNBC tomorrow @ 8:30amET. What do you want to know?,en,"[{'screen_name': 'squawkcnbc', 'name': 'squawk box', 'id': '404422077'}]",[],[],4,1,9,[],['gild'],https://twitter.com/megtirrell/status/1150502668164636672,False,https://twitter.com/JohnCendpts/status/1150473918962122752,0,,,,,,,,[],,,,
1150473918962122752,1150473918962122752,2019-07-15 00:05:31 IST,2019-07-15,00:05:31,+0530,102754598,johncendpts,John Carroll,,"Looking to resolve lingering doubts, Gilead unleashes a $5B late-stage cash alliance with Galapagos $GILD $GLPG  https://t.co/yuyXvM5peH",en,[],['https://endpts.com/looking-to-resolve-lingering-doubts-gilead-unleashes-a-5b-late-stage-cash-alliance-with-galapagos/'],[],0,16,22,[],"['gild', 'glpg']",https://twitter.com/JohnCendpts/status/1150473918962122752,False,,0,,,,,,,,[],,,,
1150467730522484736,1150467730522484736,2019-07-14 23:40:56 IST,2019-07-14,23:40:56,+0530,873399943,jacobplieth,Jacob Plieth,,$GLPG $3.95bn up front + $1.1bn equity investment from $GILD,en,[],[],[],1,1,4,[],"['glpg', 'gild']",https://twitter.com/JacobPlieth/status/1150467730522484736,False,https://twitter.com/BertrandBio/status/1150453081278222339,0,,,,,,,,[],,,,
1150437900053598208,1150437900053598208,2019-07-14 21:42:24 IST,2019-07-14,21:42:24,+0530,3203314919,cararlombardo,Cara Lombardo,,".@WSJ scoop w/ @jonathanrockoff:  Gilead's new CEO won't join the parade of pharma mega-mergers quite yet, instead will spend $5B to deepen ties with Galapagos   https://t.co/pKQLSAS7kW via @WSJ $GILD $GLPG",en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}, {'screen_name': 'jonathanrockoff', 'name': 'jonathan rockoff', 'id': '18021517'}, {'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",['https://www.wsj.com/articles/gilead-to-boost-stake-in-belgian-biotech-galapagos-as-part-of-5-1-billion-deal-11563120462?shareToken=st39bc21ab0ee84ca6b34947af2aeef4db'],[],0,18,25,[],"['gild', 'glpg']",https://twitter.com/CaraRLombardo/status/1150437900053598208,False,,0,,,,,,,,[],,,,
1149581650885353472,1149581650885353472,2019-07-12 12:59:58 IST,2019-07-12,12:59:58,+0530,873399943,jacobplieth,Jacob Plieth,,Daniel O‚ÄôDay ringing the changes at $GILD,en,[],[],[],0,0,4,[],['gild'],https://twitter.com/JacobPlieth/status/1149581650885353472,False,https://twitter.com/CarlyHFierce/status/1149449393566703617,0,,,,,,,,[],,,,
1149427514067959808,1149427514067959808,2019-07-12 02:47:29 IST,2019-07-12,02:47:29,+0530,368158573,rebeccadrobbins,Rebecca Robbins,,"In 2016, then president of $NVS, Christi Shaw took herself off a clear track to become a CEO to take care of her sister who had multiple myeloma. Her sister died.  Today, Shaw was named CEO of $GILD's anti-cancer unit Kite Pharma.   @matthewherper reports:  https://t.co/lCNz2Kd1hx",en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.statnews.com/2019/07/11/christi-shaw-inspired-by-her-sisters-cancer-named-ceo-of-kite-pharma-gileads-anti-cancer-unit/'],[],0,17,53,[],"['nvs', 'gild']",https://twitter.com/RebeccaDRobbins/status/1149427514067959808,False,,0,,,,,,,,[],,,,
1149426372617654274,1149426372617654274,2019-07-12 02:42:57 IST,2019-07-12,02:42:57,+0530,44438256,matthewherper,Matthew Herper,,I got to talk to Christi Shaw about her move to $GILD from $LLY. She has a very personal reason for caring about CAR-T therapy.   https://t.co/q8IxqUtLXK,en,[],['https://www.statnews.com/2019/07/11/christi-shaw-inspired-by-her-sisters-cancer-named-ceo-of-kite-pharma-gileads-anti-cancer-unit/'],[],0,12,39,[],"['gild', 'lly']",https://twitter.com/matthewherper/status/1149426372617654274,False,,0,,,,,,,,[],,,,
1143408644211585025,1143408644211585025,2019-06-25 12:10:38 IST,2019-06-25,12:10:38,+0530,873399943,jacobplieth,Jacob Plieth,,Maybe 2019 isn‚Äôt the year of Nash after all $CNAT $ICPT $GILD,en,[],[],[],4,3,10,[],"['cnat', 'icpt', 'gild']",https://twitter.com/JacobPlieth/status/1143408644211585025,False,https://twitter.com/kevinatgrogan/status/1143257531218825216,0,,,,,,,,[],,,,
1137142051663802369,1137142051663802369,2019-06-08 05:09:26 IST,2019-06-08,05:09:26,+0530,100024370,ophirgottlieb,Ophir Gottlieb,,"Trade Machine members I added 13 alerts for the ""Buy the Dip""trigger we just developed.  Will add more, but these were pretty easy picking:  $AAPL, $AMD, $CSCO, $NFLX, $ROKU, $LRCX, $NVDA, $GILD, $WDAY, $ATVI,  $WMT, $IBM, $NKE  Non members - come on now:  https://t.co/QxwspPzeJ9",en,[],['http://www.cmlviz.com/2019/06/06/NFLX/he-technical-trigger-that-signals-when-to-buy-the-dip-in-netflix-inc-nasdaq-nflx.html'],[],4,3,19,[],"['aapl', 'amd', 'csco', 'nflx', 'roku', 'lrcx', 'nvda', 'gild', 'wday', 'atvi', 'wmt', 'ibm', 'nke']",https://twitter.com/OphirGottlieb/status/1137142051663802369,False,,0,,,,,,,,[],,,,
1129348935993184257,1129348935993184257,2019-05-17 17:02:23 IST,2019-05-17,17:02:23,+0530,102754598,johncendpts,John Carroll,,"Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead $MOR $NVS $GILD  https://t.co/CGRcGCSduz",en,[],['https://endpts.com/better-than-car-t-already-prepping-for-a-us-launch-morphosys-preps-stellar-dlbcl-data-to-field-against-novartis-gilead/'],[],0,13,33,[],"['mor', 'nvs', 'gild']",https://twitter.com/JohnCendpts/status/1129348935993184257,False,,0,,,,,,,,[],,,,
1126595748412497926,1126595748412497926,2019-05-10 02:42:12 IST,2019-05-10,02:42:12,+0530,84684955,armstrongdrew,Drew Armstrong,,$GILD news,en,[],[],[],0,8,4,[],['gild'],https://twitter.com/ArmstrongDrew/status/1126595748412497926,False,https://twitter.com/SecAzar/status/1126593428769378304,0,,,,,,,,[],,,,
1126079441409540096,1126079441409540096,2019-05-08 16:30:35 IST,2019-05-08,16:30:35,+0530,102754598,johncendpts,John Carroll,,Gilead wagers $109M ‚Äî cash ‚Äî that this biotech can illuminate a drug discovery path pointed straight into the kidney $GILD  https://t.co/O5tgKpdaxa,en,[],['https://endpts.com/gilead-wagers-109m-cash-that-this-biotech-can-illuminate-a-drug-discovery-path-pointed-straight-into-the-kidney/'],[],1,10,28,[],['gild'],https://twitter.com/JohnCendpts/status/1126079441409540096,False,,0,,,,,,,,[],,,,
1124398037135183872,1124398037135183872,2019-05-04 01:09:17 IST,2019-05-04,01:09:17,+0530,47678782,megtirrell,Meg Tirrell,,.‚Å¶@BrianSkorney‚Å© wins analyst note title of the week. #GoT !! $GILD  https://t.co/2AA2gbbjiU,en,"[{'screen_name': 'brianskorney', 'name': 'brian skorney', 'id': '285598594'}]",[],['https://pbs.twimg.com/media/D5qqDhJX4AAyUVL.jpg'],2,6,45,['got'],['gild'],https://twitter.com/megtirrell/status/1124398037135183872,False,,1,https://pbs.twimg.com/media/D5qqDhJX4AAyUVL.jpg,,,,,,,[],,,,
1124298683913261057,1124298683913261057,2019-05-03 18:34:29 IST,2019-05-03,18:34:29,+0530,597078771,emmarcourt,Emma Court,,How many more O'Day puns from analysts will we have to endure about Gilead's new CEO? Too many I fear. $gild,en,[],[],[],0,0,6,[],['gild'],https://twitter.com/emmarcourt/status/1124298683913261057,False,,0,,,,,,,,[],,,,
1124266372421365760,1124266372421365760,2019-05-03 16:26:05 IST,2019-05-03,16:26:05,+0530,102754598,johncendpts,John Carroll,,"Dan O‚ÄôDay‚Äôs to-do list for Gilead: Recruit a Kite CEO, press the pedal on next-gen cell therapies and start buying stuff $GILD  https://t.co/YIf23c1nEc",en,[],['https://endpts.com/dan-odays-to-do-list-for-gilead-recruit-a-kite-ceo-press-the-pedal-on-next-gen-cell-therapies-and-start-buying-stuff/'],[],0,3,16,[],['gild'],https://twitter.com/JohnCendpts/status/1124266372421365760,False,,0,,,,,,,,[],,,,
1124061497490124802,1124061497490124802,2019-05-03 02:51:59 IST,2019-05-03,02:51:59,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$GILD O‚ÄôDay on M&amp;A/biz dev:  We‚Äôre best positioned to focus on our areas of expertise, but we may look elsewhere.   We can best create value with early/mid-stage assets, but we also need to look at late-stage.   So, basically, everything and nothing.",en,[],[],[],8,4,31,[],['gild'],https://twitter.com/adamfeuerstein/status/1124061497490124802,False,,0,,,,,,,,[],,,,
1124051380161982472,1124051380161982472,2019-05-03 02:11:47 IST,2019-05-03,02:11:47,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Dan O‚ÄôDay‚Äôs opening remarks on the $GILD conference call were 100% on script, meaning you‚Äôve heard the same words from every new CEO on his first conference call. I guess there‚Äôs nothing wrong with any of this, and entirely expected, just not very newsworthy.",en,[],[],[],1,1,7,[],['gild'],https://twitter.com/adamfeuerstein/status/1124051380161982472,False,,0,,,,,,,,[],,,,
1124043716975636488,1124043716975636488,2019-05-03 01:41:20 IST,2019-05-03,01:41:20,+0530,274233761,bradloncar,Brad Loncar,,$GILD Yescarta sales.  https://t.co/hP1ZAOKVXm,en,[],[],['https://pbs.twimg.com/media/D5lnzRkXkAE5ZYL.jpg'],3,8,20,[],['gild'],https://twitter.com/bradloncar/status/1124043716975636488,False,,1,https://pbs.twimg.com/media/D5lnzRkXkAE5ZYL.jpg,,,,,,,[],,,,
1124040974810918912,1124040974810918912,2019-05-03 01:30:26 IST,2019-05-03,01:30:26,+0530,872519322077470721,tdanetwork,TD Ameritrade Network,,Live earnings reaction: üìä $EXPE $CBS $GILD $ANET $FNKO $SHAK $PLNT $WW $MNST $LYV $ATVI  https://t.co/xaNgUMKq5L,en,[],['https://www.pscp.tv/w/b5tD2jFsWkVwZ3pyUFBtam58MURYeHlOenZkTVdLTQHDRB8g4UNGrimZovYYsTXIURVw2tHwBJT8YGSIWtDY'],[],0,1,8,[],"['expe', 'cbs', 'gild', 'anet', 'fnko', 'shak', 'plnt', 'ww', 'mnst', 'lyv', 'atvi']",https://twitter.com/TDANetwork/status/1124040974810918912,False,,0,,,,,,,,[],,,,
1124039073637834753,1124039073637834753,2019-05-03 01:22:53 IST,2019-05-03,01:22:53,+0530,3043828834,cgrantwsj,Charley Grant,,I remember when $GILD earnings used to be a blockbuster event.,en,[],[],[],4,0,25,[],['gild'],https://twitter.com/CGrantWSJ/status/1124039073637834753,False,,0,,,,,,,,[],,,,
1123955589250523142,1123955589250523142,2019-05-02 19:51:09 IST,2019-05-02,19:51:09,+0530,14886375,stocktwits,Stocktwits,,Earnings after the bell today:  $FNKO $SHAK $ATVI $WTW $GILD $NVAX  and more:  https://t.co/BrJnctSA18,en,[],['https://stocktwits.com/discover/earnings-calendar'],[],0,4,9,[],"['fnko', 'shak', 'atvi', 'wtw', 'gild', 'nvax']",https://twitter.com/Stocktwits/status/1123955589250523142,False,,0,,,,,,,,[],,,,
1123324131423006721,1123324131423006721,2019-05-01 02:01:57 IST,2019-05-01,02:01:57,+0530,47678782,megtirrell,Meg Tirrell,,$GILD CFO Robin Washington to step down in early 2020. She's been with GILD since 2008 and today was named to $GOOG board.  https://t.co/obCgAcBfjN,en,[],['https://www.businesswire.com/news/home/20190430006202/en/'],[],1,9,12,[],"['gild', 'goog']",https://twitter.com/megtirrell/status/1123324131423006721,False,,0,,,,,,,,[],,,,
1122844514081808385,1122844514081808385,2019-04-29 18:16:08 IST,2019-04-29,18:16:08,+0530,14886375,stocktwits,Stocktwits,,EARNINGS THIS WEEK  Mon $GOOG $SPOT Tue $AAPL $AMD $GE $SHOP  Wed $SQ $AMRN $QCOM  Thu $GILD $ATVI Fri $CELG $WYNN   https://t.co/wiZyO71Kyg,en,[],['https://www.stocktwits.com/discover/earnings-calendar'],[],3,20,33,[],"['goog', 'spot', 'aapl', 'amd', 'ge', 'shop', 'sq', 'amrn', 'qcom', 'gild', 'atvi', 'celg', 'wynn']",https://twitter.com/Stocktwits/status/1122844514081808385,False,,0,,,,,,,,[],,,,
1122547272485441536,1122547272485441536,2019-04-28 22:35:00 IST,2019-04-28,22:35:00,+0530,274233761,bradloncar,Brad Loncar,,Another big week of earnings coming up. Dan O'Day should be interesting on Thursday!  M: $MREO $NBIX T: $AMGN $EXAS $INCY $MRK W: $ACAD $AMRN $GSK T: $GILD $PTCT $SAGE $VKTX F: $IMGN $NVO  The full list:  https://t.co/5Rac7Jb1QT  https://t.co/03piSJRLn0,en,[],['https://www.loncarblog.com/april-29-earnings'],['https://pbs.twimg.com/media/D5NySktW4AUh5Yz.jpg'],1,12,36,[],"['mreo', 'nbix', 'amgn', 'exas', 'incy', 'mrk', 'acad', 'amrn', 'gsk', 'gild', 'ptct', 'sage', 'vktx', 'imgn', 'nvo']",https://twitter.com/bradloncar/status/1122547272485441536,False,,1,https://pbs.twimg.com/media/D5NySktW4AUh5Yz.jpg,,,,,,,[],,,,
1121737514728001537,1121731826865905664,2019-04-26 16:57:19 IST,2019-04-26,16:57:19,+0530,873399943,jacobplieth,Jacob Plieth,,$AZN $IONS discontinue KRAS inhibitor. What does this mean for $AMGN $MRTX ? Via @Vantageanalysis  https://t.co/QJPhPUmqfh $SNY $NVS $GILD,en,"[{'screen_name': 'vantageanalysis', 'name': 'evaluate vantage', 'id': '3033767986'}]",['http://bit.ly/2IY2k92'],[],4,7,8,[],"['azn', 'ions', 'amgn', 'mrtx', 'sny', 'nvs', 'gild']",https://twitter.com/JacobPlieth/status/1121737514728001537,False,,0,,,,,,,,[],,,,
1118163720855621632,1118163720855621632,2019-04-16 20:16:20 IST,2019-04-16,20:16:20,+0530,368158573,rebeccadrobbins,Rebecca Robbins,,.@DaphneKoller‚Å©'s machine-learning startup @insitro just landed a big deal with $GILD. It offers a test of whether artificial intelligence can remake drug development. @matthewherper and I have the story:  https://t.co/xOyABlEtVj,en,"[{'screen_name': 'daphnekoller', 'name': 'daphne koller', 'id': '853111176'}, {'screen_name': 'insitro', 'name': 'insitro', 'id': '991393490381746176'}, {'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.statnews.com/2019/04/16/in-a-test-for-ai-a-buzzy-machine-learning-inks-drug-discovery-deal-with-gilead/'],[],0,3,24,[],['gild'],https://twitter.com/RebeccaDRobbins/status/1118163720855621632,False,,0,,,,,,,,[],,,,
1118115079361376256,1118115079361376256,2019-04-16 17:03:03 IST,2019-04-16,17:03:03,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"The NASH race: A fleeting frontrunner, a stumbling giant, the heir apparent(ly) and others in biotech look to the finish line  https://t.co/lJyqROE2WV You need a cheat sheet to pick apart all those NASH drugmakers, so I created one. $ICPT $GILD $MDGL $VKTX $GNFT",en,[],['https://www.statnews.com/2019/04/16/the-nash-race-a-fleeting-frontrunner-a-stumbling-giant-and-others-in-biotech-look-to-the-finish-line/'],[],9,10,59,[],"['icpt', 'gild', 'mdgl', 'vktx', 'gnft']",https://twitter.com/adamfeuerstein/status/1118115079361376256,False,,0,,,,,,,,[],,,,
1116616119136083970,1116613460857462785,2019-04-12 13:46:43 IST,2019-04-12,13:46:43,+0530,873399943,jacobplieth,Jacob Plieth,,"A recent interview with $NOVO mentioning the company's interest in Nash, via @ByMadeleineA  https://t.co/tW4HHx6YCb $GILD",en,"[{'screen_name': 'bymadeleinea', 'name': 'madeleine armstrong', 'id': '14673628'}]",['http://bit.ly/2uYACRj'],[],0,4,7,[],"['novo', 'gild']",https://twitter.com/JacobPlieth/status/1116616119136083970,False,,0,,,,,,,,[],,,,
1116360473023094784,1116360473023094784,2019-04-11 20:50:52 IST,2019-04-11,20:50:52,+0530,368158573,rebeccadrobbins,Rebecca Robbins,,"Just finished recording @statnews podcast. We cover: üîπ a chat w @SecAzar, ft @levfacher  üîπ CFIUS &amp; @patientslikeme  üîπ animal researchers &amp; fears of firebombs üîπ $AMGN's new osteoporosis drug  üîπ $GILD layoffs Listen when the ep drops this afternoon üëá  https://t.co/0syC9RYORM",en,"[{'screen_name': 'statnews', 'name': 'stat', 'id': '3290364847'}, {'screen_name': 'secazar', 'name': 'alex azar', 'id': '956283913835614208'}, {'screen_name': 'levfacher', 'name': 'lev facher', 'id': '28454841'}, {'screen_name': 'patientslikeme', 'name': 'patientslikeme', 'id': '16933716'}]",['https://www.statnews.com/category/readout-loud/'],[],0,2,9,[],"['amgn', 'gild']",https://twitter.com/RebeccaDRobbins/status/1116360473023094784,False,,0,,,,,,,,[],,,,
1116063852762935301,1116063852762935301,2019-04-11 01:12:12 IST,2019-04-11,01:12:12,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$GILD to lay off one-fifth of sales force as financial pressures build  https://t.co/Xjq0DUSinz,en,[],['https://www.statnews.com/2019/04/10/gilead-sciences-to-lay-off-one-fifth-of-sales-force-as-financial-pressures-build/'],[],9,34,34,[],['gild'],https://twitter.com/adamfeuerstein/status/1116063852762935301,False,,0,,,,,,,,[],,,,
1115709480807862274,1115709480807862274,2019-04-10 01:44:03 IST,2019-04-10,01:44:03,+0530,14292717,petenajarian,Pete Najarian,,Bulls double money in $GILD  https://t.co/7QoHsEm60n via investitute,en,[],['http://zpr.io/gupG8'],[],0,1,9,[],['gild'],https://twitter.com/petenajarian/status/1115709480807862274,False,,0,,,,,,,,[],,,,
1113233426486833153,1113233426486833153,2019-04-03 05:45:06 IST,2019-04-03,05:45:06,+0530,15568127,themotleyfool,The Motley Fool,,"Individual drugs rise and fall, but power players like Gilead Sciences and Teva Pharmaceutical are good bets to bring out new blockbusters to replace the old ones. $GILD $TEVA  https://t.co/gEtAFJdfar",en,[],['https://www.fool.com/investing/2019/04/01/2-incredibly-cheap-pharma-stocks-to-buy-now.aspx'],[],0,3,13,[],"['gild', 'teva']",https://twitter.com/themotleyfool/status/1113233426486833153,False,,0,,,,,,,,[],,,,
1104054079993597952,1103947857848090624,2019-03-08 21:49:39 IST,2019-03-08,21:49:39,+0530,873399943,jacobplieth,Jacob Plieth,,"@gcbioinv @mcbio316 @WilliamGerber1  https://t.co/kfRrY5lqUZ Claims $AZN Calquence, $GILD tirabrutinib &amp; $BGNE zanubrutinib all have activity at C481S $ARQL $SNSS $APTO  https://t.co/poMp9QfJgb",in,[],['http://bit.ly/2H52aMZ'],['https://pbs.twimg.com/media/D1JjLCgW0AAHJD8.jpg'],4,2,11,[],"['azn', 'gild', 'bgne', 'arql', 'snss', 'apto']",https://twitter.com/JacobPlieth/status/1104054079993597952,False,,1,https://pbs.twimg.com/media/D1JjLCgW0AAHJD8.jpg,,,,,,,"[{'screen_name': 'gcbioinv', 'name': 'Dr. GC', 'id': '788375613673447424'}, {'screen_name': 'mcbio316', 'name': 'mcbio', 'id': '446784969'}, {'screen_name': 'WilliamGerber1', 'name': 'William Gerber', 'id': '1055551057'}]",,,,
1103049431878979584,1103049431878979584,2019-03-06 03:17:32 IST,2019-03-06,03:17:32,+0530,873399943,jacobplieth,Jacob Plieth,,What an excellent day to bury bad personnel news $DBVT $GILD,en,[],[],[],1,0,11,[],"['dbvt', 'gild']",https://twitter.com/JacobPlieth/status/1103049431878979584,False,,0,,,,,,,,[],,,,
1103046392610721793,1103046392610721793,2019-03-06 03:05:28 IST,2019-03-06,03:05:28,+0530,47678782,megtirrell,Meg Tirrell,,"In other departures news, $GILD head of oncology is leaving:   https://t.co/4ASInNYPNi",en,[],['https://www.businesswire.com/news/home/20190305005961/en/'],[],4,15,27,[],['gild'],https://twitter.com/megtirrell/status/1103046392610721793,False,,0,,,,,,,,[],,,,
1101476733046407175,1101476733046407175,2019-03-01 19:08:12 IST,2019-03-01,19:08:12,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Today is Daniel O‚ÄôDay‚Äôs official first day as CEO of $GILD.   Welcome, Daniel!  https://t.co/NI4nJpjVt9",en,[],[],['https://pbs.twimg.com/tweet_video_thumb/D0k7HXYXgAAXnlr.jpg'],2,6,53,[],['gild'],https://twitter.com/adamfeuerstein/status/1101476733046407175,False,,1,https://pbs.twimg.com/tweet_video_thumb/D0k7HXYXgAAXnlr.jpg,,,,,,,[],,,,
1100157629035409408,1100157629035409408,2019-02-26 03:46:33 IST,2019-02-26,03:46:33,+0530,102754598,johncendpts,John Carroll,,Sorry -- here's the right link to the $PFE story on Xeljanz warning -- could be bad news for the entire JAK inhibitor class. $LLY $ABBV $GILD  https://t.co/CGLGGSkSx2,en,[],['https://endpts.com/fda-hits-the-alarm-on-pfizers-blockbuster-xeljanz-after-a-high-dose-was-linked-to-a-higher-death-rate-severe-cardio-risks/'],[],7,19,35,[],"['pfe', 'lly', 'abbv', 'gild']",https://twitter.com/JohnCendpts/status/1100157629035409408,False,,0,,,,,,,,[],,,,
1096078771864518656,1096078771864518656,2019-02-14 21:38:38 IST,2019-02-14,21:38:38,+0530,368158573,rebeccadrobbins,Rebecca Robbins,,"Just finished recording this week's ep of our biotech podcast, ft. üîπ@matthewherper on NASH $GILD üîπ@meggophone on ketamine $JNJ üîπ@EricTopol on AI in medicine üîπ@adamfeuerstein's rage about #healthpolicyvalentines Listen when the ep drops this afternoonüëá  https://t.co/0syC9RYORM",en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}, {'screen_name': 'meggophone', 'name': 'megan thielking', 'id': '418934617'}, {'screen_name': 'erictopol', 'name': 'eric topol', 'id': '86626845'}, {'screen_name': 'adamfeuerstein', 'name': 'adam feuerstein', 'id': '102094857'}]",['https://www.statnews.com/category/readout-loud/'],[],0,0,10,['healthpolicyvalentines'],"['gild', 'jnj']",https://twitter.com/RebeccaDRobbins/status/1096078771864518656,False,,0,,,,,,,,[],,,,
1095985920782843904,1095985920782843904,2019-02-14 15:29:40 IST,2019-02-14,15:29:40,+0530,873399943,jacobplieth,Jacob Plieth,,J Baselga $AZN was just asked about cell therapy: says it will be a pillar of oncology but field is v early. Need to crack solid tumours $GILD $BMY,en,[],[],[],0,1,6,[],"['azn', 'gild', 'bmy']",https://twitter.com/JacobPlieth/status/1095985920782843904,False,,0,,,,,,,,[],,,,
1095400545077080064,1095400545077080064,2019-02-13 00:43:36 IST,2019-02-13,00:43:36,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"What‚Äôs next in NASH? Six things to know following the $GILD drug failure  https://t.co/LKrgrZWGBm $ICPT readout, takeout speculation et al.",en,[],['https://www.statnews.com/2019/02/12/whats-next-in-nash-six-things-to-know-following-the-failure-of-gileads-lead-drug-for-fatty-liver-disease/'],[],10,12,42,[],"['gild', 'icpt']",https://twitter.com/adamfeuerstein/status/1095400545077080064,False,,0,,,,,,,,[],,,,
1095314876178841602,1095314876178841602,2019-02-12 19:03:11 IST,2019-02-12,19:03:11,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Leerink‚Äôs Geoff Porges tackled $GILD‚Äôs R&amp;D un-producitivity in his research note last night. Well worth reading if you have access.,en,[],[],[],1,1,14,[],[],https://twitter.com/adamfeuerstein/status/1095314876178841602,False,https://twitter.com/AndyBiotech/status/1095313072602996736,0,,,,,,,,[],,,,
1095291918483931136,1095291918483931136,2019-02-12 17:31:57 IST,2019-02-12,17:31:57,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Remember the locker room scene from Moneyball? ""Is losing fun?"" That's how Dan O'Day should enter the $GILD building on his first day.  https://t.co/IthlklteYB via @YouTube",en,"[{'screen_name': 'youtube', 'name': 'youtube', 'id': '10228272'}]",['https://youtu.be/o9Q0kp8CMFQ'],[],0,2,18,[],['gild'],https://twitter.com/adamfeuerstein/status/1095291918483931136,False,,0,,,,,,,,[],,,,
1095083401042894848,1095083401042894848,2019-02-12 03:43:23 IST,2019-02-12,03:43:23,+0530,102094857,adamfeuerstein,Adam Feuerstein,,A fatty liver drug from $GILD posts negative results in late-stage clinical trial  https://t.co/gsOQkXqrDJ $ICPT next.,en,[],['https://www.statnews.com/2019/02/11/a-fatty-liver-drug-from-gilead-sciences-posts-negative-results-in-late-stage-clinical-trial/'],[],17,21,35,[],"['gild', 'icpt']",https://twitter.com/adamfeuerstein/status/1095083401042894848,False,,0,,,,,,,,[],,,,
1095078222604189696,1095078222604189696,2019-02-12 03:22:48 IST,2019-02-12,03:22:48,+0530,873399943,jacobplieth,Jacob Plieth,,After $GILD selonsertib's NASH flop do you feel more or less confident about $ICPT Ocaliva's Regenrate trial?,en,[],[],[],6,5,12,[],"['gild', 'icpt']",https://twitter.com/JacobPlieth/status/1095078222604189696,False,,0,,,,,,,,[],,,,
1092794822891634692,1092794822891634692,2019-02-05 20:09:23 IST,2019-02-05,20:09:23,+0530,274233761,bradloncar,Brad Loncar,,This is going to be a pretty good year for biotwitter if mid and small caps keep rallying in the face of large cap earnings pain. $GILD,en,[],[],[],3,3,19,[],['gild'],https://twitter.com/bradloncar/status/1092794822891634692,False,,0,,,,,,,,[],,,,
1092766790927769600,1092766790927769600,2019-02-05 18:18:00 IST,2019-02-05,18:18:00,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$GILD new CEO hasn‚Äôt shown up for work yet, leaving the biotech rudderless, investors anxious  https://t.co/E0aaRcF8Gl",en,[],['https://www.statnews.com/2019/02/05/gileads-new-ceo-hasnt-shown-up-for-work-yet-leaving-the-biotech-rudderless-investors-anxious/'],[],2,8,14,[],['gild'],https://twitter.com/adamfeuerstein/status/1092766790927769600,False,,0,,,,,,,,[],,,,
1092759201061965829,1092713374541070336,2019-02-05 17:47:50 IST,2019-02-05,17:47:50,+0530,873399943,jacobplieth,Jacob Plieth,,@PRB51 @RNAiAnalyst @MaverickNY More than anything else this non-cash $820m shows just how much expectations had to be stretched to account for the amount $GILD was prepared to pay for $KITE,en,[],[],[],1,0,9,[],"['gild', 'kite']",https://twitter.com/JacobPlieth/status/1092759201061965829,False,,0,,,,,,,,"[{'screen_name': 'PRB51', 'name': 'Pierre Bedard', 'id': '42932232'}, {'screen_name': 'RNAiAnalyst', 'name': 'Multivalent Dirk Haussecker', 'id': '409194010'}, {'screen_name': 'MaverickNY', 'name': 'Sally Church', 'id': '13649002'}]",,,,
1092713374541070336,1092713374541070336,2019-02-05 14:45:44 IST,2019-02-05,14:45:44,+0530,873399943,jacobplieth,Jacob Plieth,,Let me just get this straight: a PRECLINICAL asset (KITE-585) had an $820m carrying value on $GILD 's balance sheet?,en,[],[],[],8,4,53,[],['gild'],https://twitter.com/JacobPlieth/status/1092713374541070336,False,https://twitter.com/bradloncar/status/1092530215308443649,0,,,,,,,,[],,,,
1092603585299398656,1092603585299398656,2019-02-05 07:29:28 IST,2019-02-05,07:29:28,+0530,102754598,johncendpts,John Carroll,,Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated? $GILD -3.25%  https://t.co/jGnKWPXHu7,en,[],['https://endpts.com/gilead-takes-an-820m-hit-after-axing-a-kite-car-t-are-billions-more-going-to-be-incinerated/'],[],1,6,7,[],['gild'],https://twitter.com/JohnCendpts/status/1092603585299398656,False,,0,,,,,,,,[],,,,
1092544239463030784,1092544239463030784,2019-02-05 03:33:39 IST,2019-02-05,03:33:39,+0530,274233761,bradloncar,Brad Loncar,,$GILD's comment on M&amp;A: late stage opportunities are few and far between.,en,[],[],[],7,4,13,[],['gild'],https://twitter.com/bradloncar/status/1092544239463030784,False,,0,,,,,,,,[],,,,
1092538841553080320,1092538061513207812,2019-02-05 03:12:12 IST,2019-02-05,03:12:12,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"@bradloncar Perhaps out of $GILD control, but not having O‚ÄôDay start until March 1 is a missed opportunity. O‚ÄôDay being MIA at JPM and now Q4 earnings call feels wrong.",en,[],[],[],1,0,6,[],['gild'],https://twitter.com/adamfeuerstein/status/1092538841553080320,False,,0,,,,,,,,"[{'screen_name': 'bradloncar', 'name': 'Brad Loncar', 'id': '274233761'}]",,,,
1092538061513207812,1092538061513207812,2019-02-05 03:09:06 IST,2019-02-05,03:09:06,+0530,274233761,bradloncar,Brad Loncar,,The most exciting thing about $GILD's quarter was the dividend increase. Yep.,en,[],[],[],1,0,9,[],['gild'],https://twitter.com/bradloncar/status/1092538061513207812,False,,0,,,,,,,,[],,,,
1092530215308443649,1092530215308443649,2019-02-05 02:37:56 IST,2019-02-05,02:37:56,+0530,274233761,bradloncar,Brad Loncar,,$GILD also booked an $820M impairment charge for its BCMA program.,en,[],[],[],5,2,20,[],['gild'],https://twitter.com/bradloncar/status/1092530215308443649,False,,0,,,,,,,,[],,,,
1092529586666123266,1092529586666123266,2019-02-05 02:35:26 IST,2019-02-05,02:35:26,+0530,274233761,bradloncar,Brad Loncar,,$GILD Yescarta very flat Q/Q growth.  https://t.co/ANhEq1mfhn,en,[],[],['https://pbs.twimg.com/media/Dylx01tX4AAlujk.jpg'],6,12,29,[],['gild'],https://twitter.com/bradloncar/status/1092529586666123266,False,,1,https://pbs.twimg.com/media/Dylx01tX4AAlujk.jpg,,,,,,,[],,,,
1092529498799648769,1092529498799648769,2019-02-05 02:35:05 IST,2019-02-05,02:35:05,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$GILD Yescarta Q4 sales $81 million (light), full-year $264 million.",en,[],[],[],3,1,9,[],['gild'],https://twitter.com/adamfeuerstein/status/1092529498799648769,False,,0,,,,,,,,[],,,,
1092421374474403842,1092421374474403842,2019-02-04 19:25:26 IST,2019-02-04,19:25:26,+0530,14886375,stocktwits,Stocktwits,,EARNINGS THIS WEEK    Mon - $GOOGL $GILD $CLX  Tue - $SNAP $DIS $EA   Wed - $CMG $GM $SPOT  Thu - $TWTR  Fri - $GWPH $PCG     https://t.co/BrJnctSA18,en,[],['https://stocktwits.com/discover/earnings-calendar'],[],0,34,46,[],"['googl', 'gild', 'clx', 'snap', 'dis', 'ea', 'cmg', 'gm', 'spot', 'twtr', 'gwph', 'pcg']",https://twitter.com/Stocktwits/status/1092421374474403842,False,,0,,,,,,,,[],,,,
1092346545805148161,1092346545805148161,2019-02-04 14:28:05 IST,2019-02-04,14:28:05,+0530,988955288,investingcom,Investing.com,,üí∞ The biggest companies reporting their earnings on Monday...  $GOOGL $CLX $SYY $GILD   As always check our Earnings Calendar for a full listing:  https://t.co/R9a6I3VLn3  https://t.co/WcVWNio2pO,en,[],['https://invst.ly/nipz'],['https://pbs.twimg.com/media/DyjLZFCWsAUegyt.jpg'],0,3,9,[],"['googl', 'clx', 'syy', 'gild']",https://twitter.com/Investingcom/status/1092346545805148161,False,,1,https://pbs.twimg.com/media/DyjLZFCWsAUegyt.jpg,,,,,,,[],,,,
1092135633693433857,1092135633693433857,2019-02-04 00:30:00 IST,2019-02-04,00:30:00,+0530,274233761,bradloncar,Brad Loncar,,Healthcare earnings ahead this week:  M: $ALXN $GILD T: $MYGN $VRTX W: $GSK $LLY $REGN T: $ALNY $SNY $SGEN F: $IMGN  The full schedule:  https://t.co/zhtjtiRI6c  https://t.co/o04yjKJZHS,en,[],['https://www.loncarblog.com/february-4-earnings'],['https://pbs.twimg.com/media/Dya57xfX0AoKZeB.jpg'],2,4,15,[],"['alxn', 'gild', 'mygn', 'vrtx', 'gsk', 'lly', 'regn', 'alny', 'sny', 'sgen', 'imgn']",https://twitter.com/bradloncar/status/1092135633693433857,False,,1,https://pbs.twimg.com/media/Dya57xfX0AoKZeB.jpg,,,,,,,[],,,,
1088161814121041920,1088161814121041920,2019-01-24 01:19:28 IST,2019-01-24,01:19:28,+0530,102754598,johncendpts,John Carroll,,Hardest thing in the world is trying to reach Gilead media. The Great and Mighty Oz cannot see you. Will that change under Daniel O'Day? I hope so. This is so old. $GILD,en,[],[],[],1,1,8,[],['gild'],https://twitter.com/JohnCendpts/status/1088161814121041920,False,,0,,,,,,,,[],,,,
1085900320490876928,1085900320490876928,2019-01-17 19:33:06 IST,2019-01-17,19:33:06,+0530,396365748,dshaywitz,David Shaywitz,,"If u could discuss how pharma is thinking abt tech, who would u want to hear from?  The answer, I suspect, = panelists who will be joining me Monday at #PMWC19 in SV at the panel I'm chairing: heads of R&amp;D at $GILD, $BMRN, head of $REGN RGC, CMO Verily, co-founder @gnshealthcare",en,"[{'screen_name': 'gnshealthcare', 'name': 'gns healthcare', 'id': '217483047'}]",[],[],5,4,20,['pmwc19'],"['gild', 'bmrn', 'regn']",https://twitter.com/DShaywitz/status/1085900320490876928,False,,0,,,,,,,,[],,,,
1083121391522574336,1083121391522574336,2019-01-10 03:30:37 IST,2019-01-10,03:30:37,+0530,873399943,jacobplieth,Jacob Plieth,,The most important MPS data won't come until later in the year (and never mind the #JPM19 mentions by $SNY $GILD etc) $SGMO,en,[],[],[],3,2,9,['jpm19'],"['sny', 'gild', 'sgmo']",https://twitter.com/JacobPlieth/status/1083121391522574336,False,https://twitter.com/zbiotech/status/1083103714087522314,0,,,,,,,,[],,,,
1082664978732191744,1082664978732191744,2019-01-08 21:17:00 IST,2019-01-08,21:17:00,+0530,873399943,jacobplieth,Jacob Plieth,,"This BCMA antibody-drug conjugate could be on the market in 2020, $GSK says #JPM19 $CELG $BLUE $BMY $GILD",en,[],[],[],0,8,9,['jpm19'],"['gsk', 'celg', 'blue', 'bmy', 'gild']",https://twitter.com/JacobPlieth/status/1082664978732191744,False,https://twitter.com/ByMadeleineA/status/1082664294683107328,0,,,,,,,,[],,,,
1082067250897534976,1082067250897534976,2019-01-07 05:41:51 IST,2019-01-07,05:41:51,+0530,102754598,johncendpts,John Carroll,,You know that big news story that seemingly comes right on the eve of JP Morgan every year? -- this isn't it: Gilead stuffs another NASH drug discovery program into a growing portfolio $GILD  https://t.co/cGMtRZaZvI,en,[],['https://endpts.com/gilead-stuffs-another-nash-drug-discovery-program-into-a-growing-portfolio/'],[],0,4,5,[],['gild'],https://twitter.com/JohnCendpts/status/1082067250897534976,False,,0,,,,,,,,[],,,,
1081604293009068032,1081604293009068032,2019-01-05 23:02:13 IST,2019-01-05,23:02:13,+0530,102754598,johncendpts,John Carroll,,This has been nagging at me - How much does it cost to hire a top Big Pharma exec to run a biotech? Here are 4 (very) fresh examples $URGN $GILD $IRWD $AGIO  https://t.co/NhUKMDT5kb,en,[],['https://endpts.com/how-much-does-it-cost-to-hire-a-top-big-pharma-exec-to-run-a-biotech-here-are-4-very-fresh-examples/'],[],4,7,18,[],"['urgn', 'gild', 'irwd', 'agio']",https://twitter.com/JohnCendpts/status/1081604293009068032,False,,0,,,,,,,,[],,,,
1081319013593088007,1081319013593088007,2019-01-05 04:08:37 IST,2019-01-05,04:08:37,+0530,14115408,jonnajarian,Jon Najarian,,Bulls double their money in $GILD Read more:  https://t.co/hyLdzN9fEC,en,[],['http://zpr.io/gUjKw'],[],0,3,13,[],['gild'],https://twitter.com/jonnajarian/status/1081319013593088007,False,,0,,,,,,,,[],,,,
1080181201829314560,1080181201829314560,2019-01-02 00:47:21 IST,2019-01-02,00:47:21,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"No Jan. 1 price increases for $CELG $AMGN $GILD. $BIIB raised Tecfidera 6%, per ISI‚Äôs Umer Raffat.",et,[],[],[],3,3,13,[],"['celg', 'amgn', 'gild', 'biib']",https://twitter.com/adamfeuerstein/status/1080181201829314560,False,,0,,,,,,,,[],,,,
1076136246836191234,1076136246836191234,2018-12-21 20:54:09 IST,2018-12-21,20:54:09,+0530,873399943,jacobplieth,Jacob Plieth,,"Fun fact: in 24 years $AGEN turned $1.1bn of shareholder money into $300m of market cap. My take on the $GILD deal, via @Vantageanalysis  https://t.co/PF5vO119y8",en,"[{'screen_name': 'vantageanalysis', 'name': 'evaluate vantage', 'id': '3033767986'}]",['http://www.evaluate.com/vantage/articles/news/deals/christmas-comes-early-agenus'],[],3,8,15,[],"['agen', 'gild']",https://twitter.com/JacobPlieth/status/1076136246836191234,False,,0,,,,,,,,[],,,,
1073341794111377409,1073341794111377409,2018-12-14 03:50:00 IST,2018-12-14,03:50:00,+0530,368158573,rebeccadrobbins,Rebecca Robbins,,Latest ep of our biotech podcast is up. Tune in for a discussion of $GILD's new CEO and the year that was in biotech. We also interview @cecilejanssens about polygenic risk scores.  https://t.co/2B5IFrxT77,en,"[{'screen_name': 'cecilejanssens', 'name': 'cecile janssens', 'id': '2290307712'}]",['https://www.statnews.com/2018/12/13/podcast-gilead-new-ceo-genetic-tests/'],[],0,7,15,[],['gild'],https://twitter.com/RebeccaDRobbins/status/1073341794111377409,False,,0,,,,,,,,[],,,,
1072144341408407552,1072144341408407552,2018-12-10 20:31:45 IST,2018-12-10,20:31:45,+0530,295746612,faycortez,Michelle Fay Cortez,,"It will be so interesting to see how Daniel O'Day transforms $GILD, even in the narrow comms world. Roche is known for accessible and fluent executives, and he is one of the most polished. Gilead is one of the most closed shops in the industry. Something's gonna give.",en,[],[],[],0,1,24,[],['gild'],https://twitter.com/FayCortez/status/1072144341408407552,False,,0,,,,,,,,[],,,,
1072100438495948800,1072100438495948800,2018-12-10 17:37:17 IST,2018-12-10,17:37:17,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Why Gilead‚Äôs new CEO is a solid choice to help the biotech grow again  https://t.co/8EJ6xtmW6W $GILD,en,[],['https://www.statnews.com/2018/12/10/why-gileads-new-ceo-is-a-solid-choice-to-help-the-biotech-grow-again/'],[],0,11,29,[],['gild'],https://twitter.com/adamfeuerstein/status/1072100438495948800,False,,0,,,,,,,,[],,,,
1072050943108235265,1072050943108235265,2018-12-10 14:20:37 IST,2018-12-10,14:20:37,+0530,873399943,jacobplieth,Jacob Plieth,,"At $RHHBY Daniel O'Day was never an overwhelming fan of CAR-T, so it will be interesting to see what he does with the $GILD Kite business",en,[],[],[],3,3,11,[],"['rhhby', 'gild']",https://twitter.com/JacobPlieth/status/1072050943108235265,False,https://twitter.com/odibro/status/1072018945308270594,0,,,,,,,,[],,,,
1071938201886093312,1071938201886093312,2018-12-10 06:52:37 IST,2018-12-10,06:52:37,+0530,47678782,megtirrell,Meg Tirrell,,"Wow: $GILD to hire Roche‚Äôs Dan O‚ÄôDay as new CEO, per ‚Å¶‚Å¶@WSJ‚Å©   https://t.co/bf2ri5lS05",en,"[{'screen_name': 'wsj', 'name': 'the wall street journal', 'id': '3108351'}]",['https://www.wsj.com/articles/roche-executive-to-be-named-gilead-ceo-1544404654'],[],7,34,84,[],['gild'],https://twitter.com/megtirrell/status/1071938201886093312,False,,0,,,,,,,,[],,,,
1071097689209749505,1071097689209749505,2018-12-07 23:12:43 IST,2018-12-07,23:12:43,+0530,259725229,valaafshar,Vala Afshar,,20 largest market caps:  1 $MSFT 2 $AMZN 3 $AAPL 4 $GOOGL 5 $GOOG 6 $FB 7 $INTC 8 $CSCO 9 $CMCSA 10 $PEP 11 $AMGN 12 $NFLX 13 $ADBE 14 $COST 15 $PYPL 16 $NVDA 17 $AVGO 18 $TXN 19 $FOX 20 $GILD,en,[],[],[],1,10,16,[],"['msft', 'amzn', 'aapl', 'googl', 'goog', 'fb', 'intc', 'csco', 'cmcsa', 'pep', 'amgn', 'nflx', 'adbe', 'cost', 'pypl', 'nvda', 'avgo', 'txn', 'fox', 'gild']",https://twitter.com/ValaAfshar/status/1071097689209749505,False,,0,,,,,,,,[],,,,
1069408727051182080,1069408727051182080,2018-12-03 07:21:23 IST,2018-12-03,07:21:23,+0530,873399943,jacobplieth,Jacob Plieth,,"KITE-439, a TCR targeting HPV-16 E7, in HPV-16+ve epithelial cancers, via C Hinrichs. 2 of the responses are unconfirmed #ASH18 $GILD  https://t.co/RgoITdit8G",en,[],[],"['https://pbs.twimg.com/media/DtdNjkEWsAUAzEI.jpg', 'https://pbs.twimg.com/media/DtdNjkGWwAA-IeT.jpg', 'https://pbs.twimg.com/media/DtdNjkJWsAAh0F7.jpg', 'https://pbs.twimg.com/media/DtdNjkHWwAE-g7C.jpg']",6,21,52,['ash18'],['gild'],https://twitter.com/JacobPlieth/status/1069408727051182080,False,,1,https://pbs.twimg.com/media/DtdNjkEWsAUAzEI.jpg,,,,,,,[],,,,
1069279532236988416,1069279532236988416,2018-12-02 22:48:01 IST,2018-12-02,22:48:01,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Unbowed by critics, Gilead‚Äôs cancer chief pushes ahead with growth plans  https://t.co/fczEerY2iU $GILD #ASH18",en,[],['https://www.statnews.com/2018/12/02/gilead-cancer-chief-growth/'],[],1,8,15,['ash18'],['gild'],https://twitter.com/adamfeuerstein/status/1069279532236988416,False,,0,,,,,,,,[],,,,
1057613314761474049,1057613314761474049,2018-10-31 18:10:38 IST,2018-10-31,18:10:38,+0530,274233761,bradloncar,Brad Loncar,,This Tango deal is cool because it's one of the first for $GILD outside of cell therapy in IO.  https://t.co/hOyDiUoG90,en,[],['https://www.businesswire.com/news/home/20181031005225/en/'],[],2,2,7,[],['gild'],https://twitter.com/bradloncar/status/1057613314761474049,False,,0,,,,,,,,[],,,,
1055567035604832257,1055567035604832257,2018-10-26 02:39:27 IST,2018-10-26,02:39:27,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$GILD CEO John Milligan, on conference calls, says goodbye. And we say‚Ä¶  https://t.co/t6JpRB9MzI",en,[],[],['https://pbs.twimg.com/tweet_video_thumb/DqYgYG8WsAAPXia.jpg'],1,3,35,[],['gild'],https://twitter.com/adamfeuerstein/status/1055567035604832257,False,,1,https://pbs.twimg.com/tweet_video_thumb/DqYgYG8WsAAPXia.jpg,,,,,,,[],,,,
1055566139995119624,1055566139995119624,2018-10-26 02:35:53 IST,2018-10-26,02:35:53,+0530,47678782,megtirrell,Meg Tirrell,,"$GILD CEO John Milligan saying his goodbyes on earnings call now, sounding like he‚Äôs slightly choked up. He‚Äôs been at GILD 28 years.",en,[],[],[],3,17,70,[],['gild'],https://twitter.com/megtirrell/status/1055566139995119624,False,,0,,,,,,,,[],,,,
1055558911976267778,1055558911976267778,2018-10-26 02:07:10 IST,2018-10-26,02:07:10,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$GILD has a monster catalyst Q1 ‚Äô19 calendar, with ph3 readouts in NASH and RA, plus (maybe hopefully?) a new CEO.",en,[],[],[],5,4,41,[],['gild'],https://twitter.com/adamfeuerstein/status/1055558911976267778,False,,0,,,,,,,,[],,,,
1055556480047423488,1055556480047423488,2018-10-26 01:57:30 IST,2018-10-26,01:57:30,+0530,21778391,cnbcclosingbell,CNBC's Closing Bell,,After hours earnings movers - $AMZN $GOOGL $INTC $CMG $GILD $SNAP $EXPE $AKS  https://t.co/vM8irtsdFN,en,[],[],['https://pbs.twimg.com/media/DqYW6kcWoAEQZHy.jpg'],0,10,10,[],"['amzn', 'googl', 'intc', 'cmg', 'gild', 'snap', 'expe', 'aks']",https://twitter.com/CNBCClosingBell/status/1055556480047423488,False,,1,https://pbs.twimg.com/media/DqYW6kcWoAEQZHy.jpg,,,,,,,[],,,,
1055553558639046656,1055553558639046656,2018-10-26 01:45:54 IST,2018-10-26,01:45:54,+0530,14031032,adamsinger,Adam Singer,,"Large cap tech will be fine btw, unlike large cap biotech they aren't afraid to innovate / acquire and grow. Whereas a lot of the large bios are like watching paint dry. Needs bolder leadership there. We're all looking at you $GILD.",en,[],[],[],5,2,25,[],['gild'],https://twitter.com/AdamSinger/status/1055553558639046656,False,,0,,,,,,,,[],,,,
1055550782278381568,1055550782278381568,2018-10-26 01:34:52 IST,2018-10-26,01:34:52,+0530,21778391,cnbcclosingbell,CNBC's Closing Bell,,The Octobox is back in full force for earnings coverage! @dee_bosa @CNBCJosh @jonfortt @katerogers @megtirrell @seemacnbc @JBoorstin @JackieDeAngelis   $AMZN $GOOGL $INTC $CMG $GILD $EXPE $SNAP $AKS  https://t.co/zFwnPx1TIf,en,"[{'screen_name': 'dee_bosa', 'name': 'deirdre bosa', 'id': '272317020'}, {'screen_name': 'cnbcjosh', 'name': 'josh lipton', 'id': '468703129'}, {'screen_name': 'jonfortt', 'name': 'jon fortt', 'id': '26819104'}, {'screen_name': 'katerogers', 'name': 'kate rogers', 'id': '596792665'}, {'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}, {'screen_name': 'seemacnbc', 'name': 'seema mody', 'id': '61292961'}, {'screen_name': 'jboorstin', 'name': 'julia boorstin', 'id': '24266406'}, {'screen_name': 'jackiedeangelis', 'name': 'jackie deangelis', 'id': '147409568'}]",[],['https://pbs.twimg.com/media/DqYRk85X0AALCW3.jpg'],5,7,28,[],"['amzn', 'googl', 'intc', 'cmg', 'gild', 'expe', 'snap', 'aks']",https://twitter.com/CNBCClosingBell/status/1055550782278381568,False,,1,https://pbs.twimg.com/media/DqYRk85X0AALCW3.jpg,,,,,,,[],,,,
1055544737573175296,1055544737573175296,2018-10-26 01:10:51 IST,2018-10-26,01:10:51,+0530,329838136,jowens510,Jeremy C. Owens,,"Welcome to the biggest afternoon of earnings season, everyone.  Today's tech docket: $AMZN $GOOG $INTC $SNAP $EXPE $NTGR $CY $CBLK $PFPT for starters  Outside of tech, there is $CMG  $GILD $MAT $FSLR and many, many, many more",en,[],[],[],2,11,24,[],"['amzn', 'goog', 'intc', 'snap', 'expe', 'ntgr', 'cy', 'cblk', 'pfpt', 'cmg', 'gild', 'mat', 'fslr']",https://twitter.com/jowens510/status/1055544737573175296,False,,0,,,,,,,,[],,,,
1055485386116530176,1055485386116530176,2018-10-25 21:15:00 IST,2018-10-25,21:15:00,+0530,44060322,benzinga,Benzinga,,Companies Reporting Earnings After The Bell $INTC $AMZN $CMG $SNAP $GOOGL $EXPE $SAM $WDC $MAT $GILD $DFS $UHS $CERN  https://t.co/1Ys3mJvNpa,en,[],[],['https://pbs.twimg.com/media/DqWh-V_WkAAs8Hc.jpg'],0,3,5,[],"['intc', 'amzn', 'cmg', 'snap', 'googl', 'expe', 'sam', 'wdc', 'mat', 'gild', 'dfs', 'uhs', 'cern']",https://twitter.com/Benzinga/status/1055485386116530176,False,,1,https://pbs.twimg.com/media/DqWh-V_WkAAs8Hc.jpg,,,,,,,[],,,,
1054351700834758656,1054351700834758656,2018-10-22 18:10:09 IST,2018-10-22,18:10:09,+0530,14886375,stocktwits,Stocktwits,,Earnings this week  Mon - $HAL $HAS $KMB $LOGI $PETS $AMTD $SLM Tue - $VZ $CAT $MCD $LMT $JBLU $BIIB $MMM $IRBT $EW $LLY Wed - $MSFT $AMD $F $T $V $BA $UPS $VALE $LVS Thu - $TWTR $GOOGL $SNAP $AMZN $CMG $INTC $GILD $SHOP $MRK $MO Fri - $TMUS $PSX $CL $COG   https://t.co/BrJnctAYCy,en,[],['https://stocktwits.com/discover/earnings-calendar'],[],0,28,41,[],"['hal', 'has', 'kmb', 'logi', 'pets', 'amtd', 'slm', 'vz', 'cat', 'mcd', 'lmt', 'jblu', 'biib', 'mmm', 'irbt', 'ew', 'lly', 'msft', 'amd', 'f', 't', 'v', 'ba', 'ups', 'vale', 'lvs', 'twtr', 'googl', 'snap', 'amzn', 'cmg', 'intc', 'gild', 'shop', 'mrk', 'mo', 'tmus', 'psx', 'cl', 'cog']",https://twitter.com/Stocktwits/status/1054351700834758656,False,,0,,,,,,,,[],,,,
1054101264596819970,1054101264596819970,2018-10-22 01:35:00 IST,2018-10-22,01:35:00,+0530,274233761,bradloncar,Brad Loncar,,Important week of earnings coming up.  M: $IQV T: $ALKS $BIIB $ILMN W: $ALXN $SRPT $VRTX T: $BMY $CELG $GILD $MRK F: $ZBH  The full schedule:  https://t.co/HUDBDpBplJ  https://t.co/YzL4fSQats,en,[],['https://www.loncarblog.com/october-15-earnings'],['https://pbs.twimg.com/media/Dp7E80kUwAE4G1s.jpg'],1,8,22,[],"['iqv', 'alks', 'biib', 'ilmn', 'alxn', 'srpt', 'vrtx', 'bmy', 'celg', 'gild', 'mrk', 'zbh']",https://twitter.com/bradloncar/status/1054101264596819970,False,,1,https://pbs.twimg.com/media/Dp7E80kUwAE4G1s.jpg,,,,,,,[],,,,
1050135192109760525,1050135192109760525,2018-10-11 02:55:15 IST,2018-10-11,02:55:15,+0530,1413027896,charliebilello,Charlie Bilello,,% Below 52-week high... $AMGN: -4% $BRKB: -5% $JPM: -7% $AAPL: -7% $CSCO: -8% $MSFT: -9% $V: -11% $BAC: -12% $ADBE: -14% $AMZN: -14% $GOOGL: -15% $NVDA: -16% $GILD: -16% $PYPL: -20% $INTC: -22% $NFLX: -23% $FB: -31% $BIDU: -32% $BABA: -34% $TCEHY: -42% $NTES: -44% $TWTR: -44%,en,[],[],[],33,396,762,[],"['amgn', 'brkb', 'jpm', 'aapl', 'csco', 'msft', 'v', 'bac', 'adbe', 'amzn', 'googl', 'nvda', 'gild', 'pypl', 'intc', 'nflx', 'fb', 'bidu', 'baba', 'tcehy', 'ntes', 'twtr']",https://twitter.com/charliebilello/status/1050135192109760525,False,,0,,,,,,,,[],,,,
1047101917946687488,1047101917946687488,2018-10-02 18:02:06 IST,2018-10-02,18:02:06,+0530,102094857,adamfeuerstein,Adam Feuerstein,,The biotech scorecard for the fourth quarter: 12 make-or-break industry events to watch  https://t.co/YeaPO9pDEb $ALKS $GBT $REGN $VRTX $BLUE $SAGE $NBIX $GILD $ONCE $DBVT $BIIB $ESPR,en,[],['https://www.statnews.com/2018/10/02/the-biotech-scorecard-for-the-fourth-quarter-12-make-or-break-industry-events-to-watch/'],[],7,14,23,[],"['alks', 'gbt', 'regn', 'vrtx', 'blue', 'sage', 'nbix', 'gild', 'once', 'dbvt', 'biib', 'espr']",https://twitter.com/adamfeuerstein/status/1047101917946687488,False,,0,,,,,,,,[],,,,
1044249212253339648,1044249212253339648,2018-09-24 21:06:28 IST,2018-09-24,21:06:28,+0530,42703163,sarahkarlin,Sarah Karlin-Smith,,Remember when $MYL did this with EpiPen? $GILD more subtly seems to be blaming rebates and is launching authorized generics of  Harvoni &amp; Epclusa for $24K   https://t.co/faZBo1Vttj,en,[],['https://subscriber.politicopro.com/health-care/whiteboard/2018/09/gilead-launches-discounted-versions-of-hepatitis-c-drugs-1966909'],[],2,1,6,[],"['myl', 'gild']",https://twitter.com/SarahKarlin/status/1044249212253339648,False,,0,,,,,,,,[],,,,
1040655892813950976,1040655892813950976,2018-09-14 23:07:53 IST,2018-09-14,23:07:53,+0530,102754598,johncendpts,John Carroll,,"$520M plus -- After a 6-month romp, Arie Belldegrun and David Chang fly a $100M-plus IPO for off-the-shelf CAR-T player Allogene $ALLO $GILD  https://t.co/vWwhtumwar",en,[],['https://endpts.com/after-a-6-month-romp-arie-belldegrun-and-david-chang-fly-a-100m-plus-ipo-for-off-the-shelf-car-t-player-allogene/'],[],6,9,18,[],"['allo', 'gild']",https://twitter.com/JohnCendpts/status/1040655892813950976,False,,0,,,,,,,,[],,,,
1040355543129485312,1040355543129485312,2018-09-14 03:14:25 IST,2018-09-14,03:14:25,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,"$GILD down 11% over the past 12 months, but @petenajarian is pitching a break higher from here.  https://t.co/TBIjsAt8SL",en,"[{'screen_name': 'petenajarian', 'name': 'pete najarian', 'id': '14292717'}]",[],[],15,8,31,[],['gild'],https://twitter.com/CNBCFastMoney/status/1040355543129485312,False,,1,https://pbs.twimg.com/media/DnAV2W2XsAEtzuK.jpg,,,,,,,[],,,,
1039866383360827392,1039866383360827392,2018-09-12 18:50:40 IST,2018-09-12,18:50:40,+0530,102754598,johncendpts,John Carroll,,"Skirting a group of pioneers, Gilead partners with gene-editing upstart Precision Bio in hunt to cure hep B $GILD  https://t.co/vwI8URcTP8",en,[],['https://endpts.com/skirting-a-group-of-pioneers-gilead-partners-with-gene-editing-upstart-precision-bio-in-hunt-to-cure-hep-b/'],[],0,3,12,[],['gild'],https://twitter.com/JohnCendpts/status/1039866383360827392,False,,0,,,,,,,,[],,,,
1039483708854743040,1039483708854743040,2018-09-11 17:30:03 IST,2018-09-11,17:30:03,+0530,102754598,johncendpts,John Carroll,,"Joining the exodus at Gilead, CMO Andrew Cheng makes the switch to biotech CEO ‚Äî triggering a cross-country move for Akero $GILD  https://t.co/ed2eKBLSBG",en,[],['https://endpts.com/joining-the-exodus-at-gilead-cmo-andrew-cheng-makes-the-switch-to-biotech-ceo-triggering-cross-country-move-to-bay-area/'],[],0,1,5,[],['gild'],https://twitter.com/JohnCendpts/status/1039483708854743040,False,,0,,,,,,,,[],,,,
1037103745237176322,1037103745237176322,2018-09-05 03:52:55 IST,2018-09-05,03:52:55,+0530,47678782,megtirrell,Meg Tirrell,,A much-mentioned name for $GILD CEO now out of the running. Will miss interviewing David Schenkein each December at ASH!,en,[],[],[],0,2,10,[],['gild'],https://twitter.com/megtirrell/status/1037103745237176322,False,https://twitter.com/matthewherper/status/1037098716208005120,0,,,,,,,,[],,,,
1037098565254959104,1037098565254959104,2018-09-05 03:32:20 IST,2018-09-05,03:32:20,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$AGIO names a new CEO, one with commercial chops in biotech  https://t.co/X2u1AKVeUk Someone's NOT going to be $GILD new CEO.",en,[],['https://www.statnews.com/2018/09/04/agios-pharma-new-ceo-fouse/'],[],3,13,45,[],"['agio', 'gild']",https://twitter.com/adamfeuerstein/status/1037098565254959104,False,,0,,,,,,,,[],,,,
1035128298462949376,1035128298462949376,2018-08-30 17:03:12 IST,2018-08-30,17:03:12,+0530,102754598,johncendpts,John Carroll,,Amgen vet Laura Hamill takes commercial reins at Gilead amid executive shakeup $AMGN $GILD @AmberTongPW   https://t.co/lfF1XB1BWi,en,"[{'screen_name': 'ambertongpw', 'name': 'amber tong', 'id': '746441781588426752'}]",['https://endpts.com/amgen-vet-laura-hamill-takes-commercial-reins-at-gilead-amid-executive-shakeup/'],[],0,4,5,[],"['amgn', 'gild']",https://twitter.com/JohnCendpts/status/1035128298462949376,False,,0,,,,,,,,[],,,,
1034038951563153408,1034038951563153408,2018-08-27 16:54:32 IST,2018-08-27,16:54:32,+0530,102754598,johncendpts,John Carroll,,"Rarely see a partial rollout like this. How bad are $NVS manufacturing problems with CAR-T? Novartis wins a key OK for Kymriah, but continuing manufacturing woes afflict their rollout ‚Äî rival Gilead breaks into Europe $NVS $GILD  https://t.co/KENtNpnkCT",en,[],['https://endpts.com/novartis-wins-a-key-ok-for-kymriah-but-continuing-manufacturing-woes-afflict-their-rollout-rival-gilead-breaks-into-europe/'],[],3,4,8,[],"['nvs', 'nvs', 'gild']",https://twitter.com/JohnCendpts/status/1034038951563153408,False,,0,,,,,,,,[],,,,
1032656221181026305,1032656221181026305,2018-08-23 21:20:03 IST,2018-08-23,21:20:03,+0530,475309726,tradestation,TradeStation,,Biotech $IBB and healthcare $XLV have been gaining momentum since July. See why $GILD rose to the top of the list for our quant algorithm and learn more about the technology behind this analysis here  https://t.co/Prax2nGMqj  https://t.co/YXo0L2uuQE,en,[],['http://bit.ly/2NQu2nR'],['https://pbs.twimg.com/media/DlS7XCrXsAEbQ7M.jpg'],1,4,44,[],"['ibb', 'xlv', 'gild']",https://twitter.com/TradeStation/status/1032656221181026305,False,,1,https://pbs.twimg.com/media/DlS7XCrXsAEbQ7M.jpg,,,,,,,[],,,,
1032245642159120384,1032245642159120384,2018-08-22 18:08:33 IST,2018-08-22,18:08:33,+0530,102754598,johncendpts,John Carroll,,$510M and two lousy PhIIIs later -- Remember momelotinib? Gilead unloads rights to its shelved JAK inhibitor for token $3M payment $GILD $SRRA  https://t.co/CiDPIs8lpW,en,[],['https://endpts.com/remember-momelotinib-gilead-unloads-rights-to-its-shelved-jak-inhibitor-for-token-3m-payment/'],[],3,4,8,[],"['gild', 'srra']",https://twitter.com/JohnCendpts/status/1032245642159120384,False,,0,,,,,,,,[],,,,
1031966404952637440,1031966404952637440,2018-08-21 23:38:58 IST,2018-08-21,23:38:58,+0530,346605991,sxbegle,sharon begley,,"They're the Rodney Dangerfield of CAR-T cancer-fighting cells ('no respect,' for you young 'uns). Study @fredhutch says they cd be key to greater efficacy, less toxicity:  https://t.co/bTBW3QSUbH $NVS $GILD #Yescarta #Kymriah",en,"[{'screen_name': 'fredhutch', 'name': 'fred hutch', 'id': '16645335'}]",['https://www.statnews.com/2018/08/21/car-t-cancer-costimulatory-domain-molecule/'],[],0,10,25,"['yescarta', 'kymriah']","['nvs', 'gild']",https://twitter.com/sxbegle/status/1031966404952637440,False,,0,,,,,,,,[],,,,
1029473639102656523,1029473639102656523,2018-08-15 02:33:36 IST,2018-08-15,02:33:36,+0530,47678782,megtirrell,Meg Tirrell,,Exec changes at $GILD continue: CMO Andrew Cheng leaving to pursue another opportunity  https://t.co/MwPddXWLEM,en,[],['https://www.businesswire.com/news/home/20180814005715/en/'],[],0,8,13,[],['gild'],https://twitter.com/megtirrell/status/1029473639102656523,False,,0,,,,,,,,[],,,,
1028545481083895809,1028545481083895809,2018-08-12 13:05:26 IST,2018-08-12,13:05:26,+0530,873399943,jacobplieth,Jacob Plieth,,New link on new website #NASH $ICPT $GILD $GEMP $MDGL $CNAT $GNFT  https://t.co/cvB5vxOMaA,en,[],['http://www.evaluate.com/vantage/articles/analysis/spotlight/liver-disease-set-its-pivotal-year'],[],3,11,28,['nash'],"['icpt', 'gild', 'gemp', 'mdgl', 'cnat', 'gnft']",https://twitter.com/JacobPlieth/status/1028545481083895809,False,https://twitter.com/JacobPlieth/status/1027913722097008641,0,,,,,,,,[],,,,
1027913722097008641,1027913722097008641,2018-08-10 19:15:03 IST,2018-08-10,19:15:03,+0530,873399943,jacobplieth,Jacob Plieth,,"Remember when NASH was a thing? It's back, and about to enter a pivotal year. Via @EPVantage  https://t.co/mt12mqmCHG $ICPT $GILD $GEMP $MDGL $CNAT",en,"[{'screen_name': 'epvantage', 'name': 'vantage', 'id': '841963175729856512'}]",['http://www.epvantage.com/Universal/View.aspx?type=Story&id=808851&isEPVantage=yes'],[],7,10,37,[],"['icpt', 'gild', 'gemp', 'mdgl', 'cnat']",https://twitter.com/JacobPlieth/status/1027913722097008641,False,,0,,,,,,,,[],,,,
1027598152935919619,1027598152935919619,2018-08-09 22:21:06 IST,2018-08-09,22:21:06,+0530,14886375,stocktwits,Stocktwits,,"Here's a list of 27 stocks going after cancer. Including the big names like $CELG, $GILD, $PFE, and $MRK. And then several stocks you've probably never heard of. üí™   https://t.co/whcgaCb6BO",en,[],['https://stocktwits.com/discover/lists/184/the-companies-going-after-cancer'],[],1,15,28,[],"['celg', 'gild', 'pfe', 'mrk']",https://twitter.com/Stocktwits/status/1027598152935919619,False,,0,,,,,,,,[],,,,
1026887789609201669,1026887789609201669,2018-08-07 23:18:22 IST,2018-08-07,23:18:22,+0530,44438256,matthewherper,Matthew Herper,,I love this story. $GILD used to say PrEP was not a real commercial opportunity. Now it's running drug ads for it -- and seeing it as a source of growth. By @mtindera07.     https://t.co/GQLncb8kX2,en,"[{'screen_name': 'mtindera07', 'name': 'michela tindera', 'id': '23700187'}]",['https://www.forbes.com/sites/michelatindera/2018/08/07/gilead-said-prep-to-prevent-hiv-was-not-a-commercial-opportunity-now-its-running-ads-for-it/#95f56c0781bb'],[],6,5,13,[],['gild'],https://twitter.com/matthewherper/status/1026887789609201669,False,,0,,,,,,,,[],,,,
1026765685295333376,1026765685295333376,2018-08-07 15:13:10 IST,2018-08-07,15:13:10,+0530,873399943,jacobplieth,Jacob Plieth,,"Engineered TCR players $ADAP, $GILD, $MDGEF and others.",en,[],[],[],1,3,9,[],"['adap', 'gild', 'mdgef']",https://twitter.com/JacobPlieth/status/1026765685295333376,False,https://twitter.com/evaluatevantage/status/1026743366149726208,0,,,,,,,,[],,,,
1024268438632419333,1024268438632419333,2018-07-31 17:50:00 IST,2018-07-31,17:50:00,+0530,368158573,rebeccadrobbins,Rebecca Robbins,,"Here's what one biopharma VC told me: You can count manufacturing experts in cellular and gene therapy on one or two hands. A few are being held onto for dear life by $GILD, $NVS, and $CELG. And a couple others are on a beach somewhere. My story:  https://t.co/43ARs4j7nA  https://t.co/gyAoWrKCSl",en,[],['https://www.statnews.com/2018/07/31/cell-gene-therapy-expert-shortage/'],['https://pbs.twimg.com/media/Dja3MXcUwAE7upc.jpg'],1,14,23,[],"['gild', 'nvs', 'celg']",https://twitter.com/RebeccaDRobbins/status/1024268438632419333,False,,1,https://pbs.twimg.com/media/Dja3MXcUwAE7upc.jpg,,,,,,,[],,,,
1023929552979062784,1023929552979062784,2018-07-30 19:23:23 IST,2018-07-30,19:23:23,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"RBC‚Äôs Brian Abrahams also weighed in today on $GILD CEO candidates, based on his conversations with investors.  Fouse favored, by far.  Also mentioned: Jeff Leiden (via a $VRTX GILD merger) Roger Perlmutter David Hung",en,[],[],[],5,2,9,[],"['gild', 'vrtx']",https://twitter.com/adamfeuerstein/status/1023929552979062784,False,,0,,,,,,,,[],,,,
1023873463478640640,1023873463478640640,2018-07-30 15:40:30 IST,2018-07-30,15:40:30,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$GILD board is looking for a new CEO. Here‚Äôs a list of possible contenders  https://t.co/RBjiHHihgl,en,[],['https://www.statnews.com/2018/07/30/gilead-sciences-ceo-contenders/'],[],3,7,13,[],['gild'],https://twitter.com/adamfeuerstein/status/1023873463478640640,False,,0,,,,,,,,[],,,,
1022579752270323712,1022579752270323712,2018-07-27 01:59:46 IST,2018-07-27,01:59:46,+0530,368158573,rebeccadrobbins,Rebecca Robbins,,"On this week's episode of The Readout LOUD, we ask: üîπWhat qualifies as ‚Äúrobust‚Äù when it comes to data? (ft. $BIIB) üîπAre VCs making wise investments in digital health? (ft. @VentureValkyrie) üîπCan $GILD survive without men named John? (ft. @MariahCarey)  https://t.co/PmUxLPNiTt",en,"[{'screen_name': 'venturevalkyrie', 'name': 'lisa suennen', 'id': '169944507'}, {'screen_name': 'mariahcarey', 'name': 'mariah carey', 'id': '19248106'}]",['https://www.statnews.com/2018/07/26/podcast-alzheimers-gilead-smart-money/'],[],1,5,12,[],"['biib', 'gild']",https://twitter.com/RebeccaDRobbins/status/1022579752270323712,False,,0,,,,,,,,[],,,,
1022433665312337926,1022433665312337926,2018-07-26 16:19:16 IST,2018-07-26,16:19:16,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$BIIB $GILD $VRTX now $ALXN all solid Q2 earnings. Q2 is supposed to be strong but still nice to see them actually deliver. $CELG on deck.,en,[],[],[],0,3,21,[],"['biib', 'gild', 'vrtx', 'alxn', 'celg']",https://twitter.com/adamfeuerstein/status/1022433665312337926,False,,0,,,,,,,,[],,,,
1022300111739731968,1022300111739731968,2018-07-26 07:28:34 IST,2018-07-26,07:28:34,+0530,274233761,bradloncar,Brad Loncar,,A trip down $GILD leadership memory lane.  https://t.co/LaYTLQp8sx,en,[],['http://www.gilead.com/news/press-releases/1997/1/donald-h-rumsfeld-named-chairman-of-gilead-sciences'],[],0,2,16,[],['gild'],https://twitter.com/bradloncar/status/1022300111739731968,False,,0,,,,,,,,[],,,,
1022240602963038210,1022240602963038210,2018-07-26 03:32:06 IST,2018-07-26,03:32:06,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$VRTX really needs to work on the timing of their earnings call. A really good quarter and CF triple update basically lost in a blizzard of $GILD $BIIB news.,en,[],[],[],2,5,23,[],"['vrtx', 'gild', 'biib']",https://twitter.com/adamfeuerstein/status/1022240602963038210,False,,0,,,,,,,,[],,,,
1022236216035614725,1022236216035614725,2018-07-26 03:14:40 IST,2018-07-26,03:14:40,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Gilead‚Äôs golden era ends with the executive departures of ‚ÄòThe Johns‚Äô  https://t.co/nefwzQ5DDP My thoughts on the exits of Milligan and Martin, and the questions for the company they leave behind. $GILD",en,[],['https://www.statnews.com/2018/07/25/gileads-golden-era-ends-with-the-executive-departures-of-the-johns/'],[],2,4,9,[],['gild'],https://twitter.com/adamfeuerstein/status/1022236216035614725,False,,0,,,,,,,,[],,,,
1022235532573728770,1022235532573728770,2018-07-26 03:11:57 IST,2018-07-26,03:11:57,+0530,47678782,megtirrell,Meg Tirrell,,"‚ÄúDon‚Äôt worry, my daughter told me she‚Äôs going to teach me how to set up a LinkedIn profile,‚Äù outgoing $GILD CEO John Milligan says of departure",en,[],[],[],3,12,79,[],['gild'],https://twitter.com/megtirrell/status/1022235532573728770,False,,0,,,,,,,,[],,,,
1022235401573019648,1022235401573019648,2018-07-26 03:11:26 IST,2018-07-26,03:11:26,+0530,274233761,bradloncar,Brad Loncar,,John Milligan has been at $GILD for almost 30 years. It was a private startup back then. üëèüëè,en,[],[],[],2,11,53,[],['gild'],https://twitter.com/bradloncar/status/1022235401573019648,False,,0,,,,,,,,[],,,,
1022230939613757441,1022230939613757441,2018-07-26 02:53:42 IST,2018-07-26,02:53:42,+0530,47678782,megtirrell,Meg Tirrell,,"So, what are the chances we get another female big biopharma CEO? $GILD",en,[],[],[],10,4,58,[],['gild'],https://twitter.com/megtirrell/status/1022230939613757441,False,,0,,,,,,,,[],,,,
1022227688612921349,1022227688612921349,2018-07-26 02:40:47 IST,2018-07-26,02:40:47,+0530,6810242,bydavidcrow,David Crow,,"""Nothing to see here"" says Mizuho on Gilead CEO exit. He's been CEO for TWO YEARS! $GILD  https://t.co/0GQJLXNW7P",en,[],[],['https://pbs.twimg.com/media/Di-upj-XgAECiNd.jpg'],1,0,5,[],['gild'],https://twitter.com/bydavidcrow/status/1022227688612921349,False,,1,https://pbs.twimg.com/media/Di-upj-XgAECiNd.jpg,,,,,,,[],,,,
1022224956392796160,1022203547000045568,2018-07-26 02:29:56 IST,2018-07-26,02:29:56,+0530,329838136,jowens510,Jeremy C. Owens,,"Heck of an afternoon so far, my friends.  $FB down 7%+ as user growth takes a hit.  https://t.co/F4VgUksqVe  $AMD up 6%+ after most profitable quarter in 7 years  https://t.co/BMrfzM1Qbx  $QCOM did what we thought  https://t.co/xoWbrJgELL  $GILD CEO is out.  https://t.co/Zzyyk3KQwq",en,[],"['https://on.mktw.net/2mK3Ejy', 'https://on.mktw.net/2mK3EQA', 'https://on.mktw.net/2mKeOol', 'https://on.mktw.net/2mHPvDh']",[],1,5,12,[],"['fb', 'amd', 'qcom', 'gild']",https://twitter.com/jowens510/status/1022224956392796160,False,,0,,,,,,,,[],,,,
1022214253099601920,1022214253099601920,2018-07-26 01:47:24 IST,2018-07-26,01:47:24,+0530,102754598,johncendpts,John Carroll,,Help wanted: New CEO to run Gilead as John Milligan steps down $GILD  https://t.co/AldkWpeIGo,en,[],['https://endpts.com/help-wanted-new-ceo-to-run-gilead-as-john-milligan-steps-down/'],[],2,8,7,[],['gild'],https://twitter.com/JohnCendpts/status/1022214253099601920,False,,0,,,,,,,,[],,,,
1022211125209903104,1022211125209903104,2018-07-26 01:34:58 IST,2018-07-26,01:34:58,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$GILD - Both Johns are leaving.   Milligan (CEO) out at end of year Martin (Chairman) out when new CEO is hired.   End of an era.,en,[],[],[],3,7,20,[],['gild'],https://twitter.com/adamfeuerstein/status/1022211125209903104,False,,0,,,,,,,,[],,,,
1022207287493054465,1022207287493054465,2018-07-26 01:19:43 IST,2018-07-26,01:19:43,+0530,274233761,bradloncar,Brad Loncar,,"Before the big $BIIB news tonight, we'll get $GILD earnings.   Consensus for HCV revenue is $946M and consensus for total revenue is $5.187B.",en,[],[],[],4,3,6,[],"['biib', 'gild']",https://twitter.com/bradloncar/status/1022207287493054465,False,,0,,,,,,,,[],,,,
1021866484908343296,1021866484908343296,2018-07-25 02:45:30 IST,2018-07-25,02:45:30,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,"It's the busiest week of the earnings season and the traders play trade it or fade it with some of the big names due to report: $FB, $MCD, $BA and $GILD  https://t.co/cimx2zgfbd",en,[],[],[],7,7,16,[],"['fb', 'mcd', 'ba', 'gild']",https://twitter.com/CNBCFastMoney/status/1021866484908343296,False,,1,https://pbs.twimg.com/media/Di5mJh6WsAAEI6M.jpg,,,,,,,[],,,,
1021865861324460032,1021865861324460032,2018-07-25 02:43:01 IST,2018-07-25,02:43:01,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,Prepare for some waves this week with some massive earnings on deck including $MCD $BA $FB and $GILD  https://t.co/C8znjmZfK7,en,[],[],['https://pbs.twimg.com/media/Di5lgPeWsAALuka.jpg'],1,4,11,[],"['mcd', 'ba', 'fb', 'gild']",https://twitter.com/CNBCFastMoney/status/1021865861324460032,False,,1,https://pbs.twimg.com/media/Di5lgPeWsAALuka.jpg,,,,,,,[],,,,
1021810216256589824,1021810216256589824,2018-07-24 23:01:54 IST,2018-07-24,23:01:54,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Adherence to PrEP, the HIV prevention drug, is low. A new study suggests a pill with a tiny sensor...  https://t.co/5U0xCE5zv6 via @atjustinchen $GILD",en,"[{'screen_name': 'atjustinchen', 'name': 'justin chen', 'id': '980625231478951937'}]",['https://www.statnews.com/2018/07/24/digital-pill-prep-truvada/'],[],0,0,7,[],['gild'],https://twitter.com/adamfeuerstein/status/1021810216256589824,False,,0,,,,,,,,[],,,,
1021422479489880066,1021422479489880066,2018-07-23 21:21:10 IST,2018-07-23,21:21:10,+0530,14886375,stocktwits,Stocktwits,,Here's who reports earnings this week üöÄ  Mon - $GOOGL $GOOG $STLD $WHR $ZION Tue - $T $VZ $LMT $JBLU $BIIB $IRBT $MMM $LLY $TXN Wed - $FB $AMD $F $GILD $PYPL $V $BA $HM $KO $ABX Thu - $AMZN $INTC $SBUX $CMG $FSRL $SPOT $MCD Fri - $TWTR $XOM $ABBV $CVX   https://t.co/BrJnctSA18,en,[],['https://stocktwits.com/discover/earnings-calendar'],[],1,43,85,[],"['googl', 'goog', 'stld', 'whr', 'zion', 't', 'vz', 'lmt', 'jblu', 'biib', 'irbt', 'mmm', 'lly', 'txn', 'fb', 'amd', 'f', 'gild', 'pypl', 'v', 'ba', 'hm', 'ko', 'abx', 'amzn', 'intc', 'sbux', 'cmg', 'fsrl', 'spot', 'mcd', 'twtr', 'xom', 'abbv', 'cvx']",https://twitter.com/Stocktwits/status/1021422479489880066,False,,0,,,,,,,,[],,,,
1021080683429572609,1021080683429572609,2018-07-22 22:43:00 IST,2018-07-22,22:43:00,+0530,274233761,bradloncar,Brad Loncar,,Huge week ahead. A link to the full earnings schedule is below.  M: $VCYT T: $BIIB $LLY W: $GILD $GSK $VRTX T: $AMGN $AZN $BMY $CELG F: $ABBV $HCM $MRK  The full schedule:  https://t.co/rn6VLD5Ugc  https://t.co/hd6jr5SaX2,en,[],['http://www.loncarblog.com/july-23-earnings'],['https://pbs.twimg.com/media/Diq2C27U0AA4OxO.jpg'],2,17,37,[],"['vcyt', 'biib', 'lly', 'gild', 'gsk', 'vrtx', 'amgn', 'azn', 'bmy', 'celg', 'abbv', 'hcm', 'mrk']",https://twitter.com/bradloncar/status/1021080683429572609,False,,1,https://pbs.twimg.com/media/Diq2C27U0AA4OxO.jpg,,,,,,,[],,,,
1020314115963871234,714847898685599745,2018-07-20 19:56:56 IST,2018-07-20,19:56:56,+0530,873399943,jacobplieth,Jacob Plieth,,Lots of interest in gamma-delta T cell therapeutics of late. I took a look at the key players:  https://t.co/9gDCssNkpT $GILD $BLUE $SHPG,en,[],['http://www.epvantage.com/Universal/View.aspx?type=Story&id=804330&isEPVantage=yes'],[],3,8,16,[],"['gild', 'blue', 'shpg']",https://twitter.com/JacobPlieth/status/1020314115963871234,False,,0,,,,,,,,[],,,,
1019927400539443200,714847898685599745,2018-07-19 18:20:16 IST,2018-07-19,18:20:16,+0530,873399943,jacobplieth,Jacob Plieth,,Now $GILD Kite buys into gamma-delta T cells  https://t.co/Zrd718DF1N,en,[],['http://www.b3cnewswire.com/201807191809/kite-and-gadeta-announce-strategic-collaboration-to-advance-gamma-delta-t-cell-receptor-technology-for-solid-tumors.html'],[],1,5,8,[],['gild'],https://twitter.com/JacobPlieth/status/1019927400539443200,False,,0,,,,,,,,[],,,,
1019340058606948352,1019340058606948352,2018-07-18 03:26:23 IST,2018-07-18,03:26:23,+0530,102094857,adamfeuerstein,Adam Feuerstein,,The first four paragraphs of this $GILD bear thesis is probably the stupidest article ever published on Seeking Alpha.  https://t.co/E8HFpixVQA,en,[],['https://seekingalpha.com/article/4187810-gileads-hiv-franchise-assault-stares-paradigm-changing-drug'],[],14,5,35,[],['gild'],https://twitter.com/adamfeuerstein/status/1019340058606948352,False,,0,,,,,,,,[],,,,
1017749265702096896,1017749265702096896,2018-07-13 18:05:08 IST,2018-07-13,18:05:08,+0530,15568127,themotleyfool,The Motley Fool,,"After a rough few years, there are 3 solid reasons to believe this biotech‚Äôs rebound in on the way. $GILD  https://t.co/3hrgChFd6f",en,[],['https://www.fool.com/investing/2018/07/12/if-youre-thinking-about-buying-gilead-sciences-sto.aspx'],[],1,6,16,[],['gild'],https://twitter.com/themotleyfool/status/1017749265702096896,False,,0,,,,,,,,[],,,,
1017038640327872512,1017038640327872512,2018-07-11 19:01:22 IST,2018-07-11,19:01:22,+0530,16838276,philstockworld,Phil Davis,,Philstockworld July Top Trade Review $AAPL $IBM $SPY $WSM $TGT $GILD $CELG #TradeIdeas --  https://t.co/pZ489Fw6KK  https://t.co/qpUd7bBzOm,en,[],['https://www.philstockworld.com/2018/07/11/philstockworld-july-top-trade-review/'],['https://pbs.twimg.com/media/Dh0_OpgWsAAvypn.jpg'],0,0,12,['tradeideas'],"['aapl', 'ibm', 'spy', 'wsm', 'tgt', 'gild', 'celg']",https://twitter.com/philstockworld/status/1017038640327872512,False,,1,https://pbs.twimg.com/media/Dh0_OpgWsAAvypn.jpg,,,,,,,[],,,,
1015340374263558146,1015340374263558146,2018-07-07 02:33:03 IST,2018-07-07,02:33:03,+0530,16732770,cnbcfastmoney,CNBC's Fast Money,,Drug stocks like $BIIB $REGN and $GILD were on a high this week.  https://t.co/SxmJdhtlij,en,[],[],['https://pbs.twimg.com/media/Dhc2mPvUYAAgjvV.jpg'],2,1,16,[],"['biib', 'regn', 'gild']",https://twitter.com/CNBCFastMoney/status/1015340374263558146,False,,1,https://pbs.twimg.com/media/Dhc2mPvUYAAgjvV.jpg,,,,,,,[],,,,
1015334627492364296,1015334627492364296,2018-07-07 02:10:13 IST,2018-07-07,02:10:13,+0530,14292717,petenajarian,Pete Najarian,,"Into the weekend, a short list of Names not FANG that traded up over 1%: $AAPL, $MSFT, $INTC, $AMD, $TWTR, $GILD, $MCD, $BIIB, $FCX, $BIDU, $CELG, $DISH, $AMGN",en,[],[],[],7,2,31,[],"['aapl', 'msft', 'intc', 'amd', 'twtr', 'gild', 'mcd', 'biib', 'fcx', 'bidu', 'celg', 'dish', 'amgn']",https://twitter.com/petenajarian/status/1015334627492364296,False,,0,,,,,,,,[],,,,
1009005916258267136,1009005916258267136,2018-06-19 15:02:11 IST,2018-06-19,15:02:11,+0530,104257356,briansozzi,Brian Sozzi,,Paying careful attention to the GLUM Index today!  https://t.co/oCTYRLxn9M @jimcramer   $CAT $BA $MMM $GE $JNJ $C $GS $LEN $WMT $F $GILD $CELG,en,"[{'screen_name': 'jimcramer', 'name': 'jim cramer', 'id': '14216123'}]",['http://ow.ly/nvLP30kyQEt'],[],0,14,25,[],"['cat', 'ba', 'mmm', 'ge', 'jnj', 'c', 'gs', 'len', 'wmt', 'f', 'gild', 'celg']",https://twitter.com/BrianSozzi/status/1009005916258267136,False,,0,,,,,,,,[],,,,
1002555875863793664,1002555875863793664,2018-06-01 19:52:02 IST,2018-06-01,19:52:02,+0530,274233761,bradloncar,Brad Loncar,,Great slide from Oppenheimer illustrates how all the action in our sector over the last year has been from mid and small cap companies. Large caps like $CELG $GILD etc not so much.  https://t.co/SbBXdrmEoz,en,[],[],['https://pbs.twimg.com/media/DenLP6AU8AAplg-.jpg'],3,5,18,[],"['celg', 'gild']",https://twitter.com/bradloncar/status/1002555875863793664,False,,1,https://pbs.twimg.com/media/DenLP6AU8AAplg-.jpg,,,,,,,[],,,,
1001914717533818880,1001914717533818880,2018-05-31 01:24:17 IST,2018-05-31,01:24:17,+0530,47678782,megtirrell,Meg Tirrell,,"I've reached out to some of the US's largest drugmakers on this. Responses so far: $GILD: No comment. $REGN: ""We are not familiar with these plans, but Regeneron has always worked to price our innovative medicines responsibly and ensure affordability for patients.""  https://t.co/hAanFjwPi8",en,[],['https://twitter.com/megtirrell/status/1001875972277329920'],[],2,5,18,[],"['gild', 'regn']",https://twitter.com/megtirrell/status/1001914717533818880,False,https://twitter.com/megtirrell/status/1001875972277329920,0,,,,,,,,[],,,,
999249458524278785,999249458524278785,2018-05-23 16:53:30 IST,2018-05-23,16:53:30,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Former $GILD CSO Norbert Bischofberger has a new job as CEO of a cancer drug startup. He also thinks AI in healthcare is overhyped. In today‚Äôs Readout newsletter.  https://t.co/SsIdg9LIH9,en,[],['https://us11.campaign-archive.com/?u=f8609630ae206654824f897b6&id=bad583f077'],[],1,3,16,[],['gild'],https://twitter.com/adamfeuerstein/status/999249458524278785,False,,0,,,,,,,,[],,,,
998954430254014465,998954430254014465,2018-05-22 21:21:10 IST,2018-05-22,21:21:10,+0530,873399943,jacobplieth,Jacob Plieth,,"$CLVS is up 4% because, if $GILD buys $TSRO, that's obviously great for $CLVS, right?",en,[],[],[],2,1,9,[],"['clvs', 'gild', 'tsro', 'clvs']",https://twitter.com/JacobPlieth/status/998954430254014465,False,,0,,,,,,,,[],,,,
997152028496363521,997152028496363521,2018-05-17 21:59:04 IST,2018-05-17,21:59:04,+0530,47678782,megtirrell,Meg Tirrell,,"FDA publishes list of drugs for which it‚Äôs received inquiries from generic manufacturers indicating they can‚Äôt get access. Among highest #s: $CELG 31 (8 Pomalyst, 13 Revlimid, 10 Thalomid) $ATLN 22 (8 Opsumit, 14 Tracleer) $GILD 11 (10 Letairis, 1 Truvada)  https://t.co/SHlFUYK4Yn",en,[],['https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm607738.htm'],[],4,14,11,['s'],"['celg', 'atln', 'gild']",https://twitter.com/megtirrell/status/997152028496363521,False,,0,,,,,,,,[],,,,
997106407446007808,997105664110493696,2018-05-17 18:57:47 IST,2018-05-17,18:57:47,+0530,57124794,annaedney,Anna Edney,,"Companies that top the naughty list: Celgene, Gilead, Novartis  $CELG $GILD $NOVN",en,[],[],[],2,5,13,[],"['celg', 'gild', 'novn']",https://twitter.com/annaedney/status/997106407446007808,False,,0,,,,,,,,[],,,,
997092167523950592,997092167523950592,2018-05-17 18:01:12 IST,2018-05-17,18:01:12,+0530,102754598,johncendpts,John Carroll,,Umer Raffat calls the Kymriah / Yescarta study provocative -- but he wants to see more details.  Watch it -- this could get a lot of attention. $NVS $GILD  https://t.co/CEeNv3sow9,en,[],['https://endpts.com/the-top-winners-and-losers-on-asco-abstract-night-loxo-blueprint-jounce-merck-kgaa-and-more/'],[],1,2,5,[],"['nvs', 'gild']",https://twitter.com/JohnCendpts/status/997092167523950592,False,,0,,,,,,,,[],,,,
996385532736409600,996385532736409600,2018-05-15 19:13:17 IST,2018-05-15,19:13:17,+0530,102754598,johncendpts,John Carroll,,"Gilead fortifies its cell therapy status, expanding into three new facilities and teaming with NCI $GILD  https://t.co/sHZ4OFFnvq",en,[],['https://endpts.com/gilead-fortifies-its-cell-therapy-status-expanding-into-three-new-facilities-and-teaming-with-nci/'],[],0,5,12,[],['gild'],https://twitter.com/JohnCendpts/status/996385532736409600,False,,0,,,,,,,,[],,,,
994717833497104384,994717202812153856,2018-05-11 04:46:27 IST,2018-05-11,04:46:27,+0530,274233761,bradloncar,Brad Loncar,,Other recent names include:  Dodgers Merger Sub = $GILD + $KITE Blue Magpie Corp = $CELG + $JUNO,en,[],[],[],2,0,6,[],"['gild', 'kite', 'celg', 'juno']",https://twitter.com/bradloncar/status/994717833497104384,False,,0,,,,,,,,[],,,,
994642032273559552,994642032273559552,2018-05-10 23:45:14 IST,2018-05-10,23:45:14,+0530,15568127,themotleyfool,The Motley Fool,,"Have you *ever* had a 100-bagger in your portfolio? It took them a couple decades, but $BIIB $CELG and $GILD all pulled off that massive growth feat.  https://t.co/LJyldaRPUI",en,[],['https://www.fool.com/investing/2018/05/09/3-stocks-that-turned-10000-into-1-million.aspx'],[],1,5,24,[],"['biib', 'celg', 'gild']",https://twitter.com/themotleyfool/status/994642032273559552,False,,0,,,,,,,,[],,,,
993817606145675266,993817606145675266,2018-05-08 17:09:16 IST,2018-05-08,17:09:16,+0530,102754598,johncendpts,John Carroll,,The (new) top 10 pharma companies by 2017 revenue -- adds Takeda/$SHPG plus $GILD  https://t.co/KMy4Qy5SkX,en,[],['https://endpts.com/the-new-top-10-pharma-companies-by-2017-revenue/'],[],3,29,55,[],['gild'],https://twitter.com/JohnCendpts/status/993817606145675266,False,,0,,,,,,,,[],,,,
991690286840664064,991689854118498305,2018-05-02 20:16:03 IST,2018-05-02,20:16:03,+0530,873399943,jacobplieth,Jacob Plieth,,$NVS $GILD cc @VinayPrasadMD  https://t.co/AVDpXW7UWr,de,[],[],['https://pbs.twimg.com/media/DcMxAtyW0AIjMnP.jpg'],2,4,17,[],"['nvs', 'gild']",https://twitter.com/JacobPlieth/status/991690286840664064,False,,1,https://pbs.twimg.com/media/DcMxAtyW0AIjMnP.jpg,,,,,,,[],,,,
991689854118498305,991689854118498305,2018-05-02 20:14:20 IST,2018-05-02,20:14:20,+0530,873399943,jacobplieth,Jacob Plieth,,Why does Kymriah's DLBCL label exclude 58% of patients enrolled into Juliet? Via @EPVantage  https://t.co/7mbLW7xSeh $NVS $GILD $CELG,en,"[{'screen_name': 'epvantage', 'name': 'vantage', 'id': '841963175729856512'}]",['http://epvantage.com/Universal/View.aspx?type=Story&id=784649&isEPVantage=yes'],[],3,12,22,[],"['nvs', 'gild', 'celg']",https://twitter.com/JacobPlieth/status/991689854118498305,False,,0,,,,,,,,[],,,,
991592080270032896,991592080270032896,2018-05-02 13:45:49 IST,2018-05-02,13:45:49,+0530,873399943,jacobplieth,Jacob Plieth,,If you're trying to figure out the numbers on Kymriah's US DLBCL label this was the state of play at #ASH17  https://t.co/QUOx8OwGz5 $NVS $GILD $CELG  https://t.co/9s1SXoEVKx,en,[],['http://bit.ly/2Kt3Ga9'],['https://pbs.twimg.com/media/DcLXoq7X0AEKjYh.jpg'],0,6,18,['ash17'],"['nvs', 'gild', 'celg']",https://twitter.com/JacobPlieth/status/991592080270032896,False,,1,https://pbs.twimg.com/media/DcLXoq7X0AEKjYh.jpg,,,,,,,[],,,,
991424611291037696,991424611291037696,2018-05-02 02:40:21 IST,2018-05-02,02:40:21,+0530,44438256,matthewherper,Matthew Herper,,$GILD seeing good reimbursement for Yescarta in both commercial and Medicare populations.,en,[],[],[],0,1,8,[],['gild'],https://twitter.com/matthewherper/status/991424611291037696,False,,0,,,,,,,,[],,,,
991424401798295553,991424401798295553,2018-05-02 02:39:31 IST,2018-05-02,02:39:31,+0530,20562637,businessinsider,Business Insider,,A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to treat more patients $NVS $GILD  https://t.co/Z6eRWLgfXB  https://t.co/M7biYbws5M,en,[],['https://read.bi/2w6idoW'],['https://pbs.twimg.com/media/DcI_PT_W4AEOOfq.jpg'],0,14,26,[],"['nvs', 'gild']",https://twitter.com/BusinessInsider/status/991424401798295553,False,,1,https://pbs.twimg.com/media/DcI_PT_W4AEOOfq.jpg,,,,,,,[],,,,
991422726014423042,991422726014423042,2018-05-02 02:32:52 IST,2018-05-02,02:32:52,+0530,102754598,johncendpts,John Carroll,,#3 Gilead joins the lineup of big biopharma partners to ally with Verily ‚Äî this time focused on immunology $GILD  https://t.co/austsLDo3T,en,[],['https://endpts.com/gilead-joins-the-lineup-of-big-biopharma-partners-to-ally-with-verily-this-time-focused-on-immunology/'],[],0,2,5,[],['gild'],https://twitter.com/JohnCendpts/status/991422726014423042,False,,0,,,,,,,,[],,,,
991421881407410176,991421881407410176,2018-05-02 02:29:30 IST,2018-05-02,02:29:30,+0530,295746612,faycortez,Michelle Fay Cortez,,Small bright spot for $GILD on Yescarta - blowing past the $16 million estimate from analysts with a $40 million first full quarter on the market. The FDA's approval of Novartis' Kymriah for DLBCL means that was its only full quarter without competition. Nothing lasts.,en,[],[],[],0,4,7,[],['gild'],https://twitter.com/FayCortez/status/991421881407410176,False,,0,,,,,,,,[],,,,
991421712146337792,991421712146337792,2018-05-02 02:28:50 IST,2018-05-02,02:28:50,+0530,274233761,bradloncar,Brad Loncar,,$GILD HCV sales over time. Credit to them for curing so many patients.   Now moving on and aiming to do the same for cancer.  https://t.co/BoRIpYjHlB,en,[],[],['https://pbs.twimg.com/media/DcI8j3JVwAATIfP.jpg'],3,24,82,[],['gild'],https://twitter.com/bradloncar/status/991421712146337792,False,,1,https://pbs.twimg.com/media/DcI8j3JVwAATIfP.jpg,,,,,,,[],,,,
991410599115526147,991410599115526147,2018-05-02 01:44:41 IST,2018-05-02,01:44:41,+0530,102094857,adamfeuerstein,Adam Feuerstein,,There are 2 slides on HepC in $GILD Q1 presentation.  https://t.co/bvR8AWwSlj,en,[],[],['https://pbs.twimg.com/tweet_video_thumb/DcIyp0hV0AAodPy.jpg'],2,0,15,[],['gild'],https://twitter.com/adamfeuerstein/status/991410599115526147,False,,1,https://pbs.twimg.com/tweet_video_thumb/DcIyp0hV0AAodPy.jpg,,,,,,,[],,,,
991410110848258050,991410110848258050,2018-05-02 01:42:44 IST,2018-05-02,01:42:44,+0530,130289750,maxnisen,Max Nisen,,Is it such a shock that the $GILD numbers are awful? That massive $ABBV HCV beat had to come from somewhere...,en,[],[],[],0,2,11,[],"['gild', 'abbv']",https://twitter.com/MaxNisen/status/991410110848258050,False,,0,,,,,,,,[],,,,
991409236998541312,991409236998541312,2018-05-02 01:39:16 IST,2018-05-02,01:39:16,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$GILD Q1 Biktarvy sales $35M light of $47M consensus. Approved Feb. 7, so less than 1 quarter on the market.",en,[],[],[],2,2,11,[],['gild'],https://twitter.com/adamfeuerstein/status/991409236998541312,False,,0,,,,,,,,[],,,,
991408464613269504,991408464613269504,2018-05-02 01:36:12 IST,2018-05-02,01:36:12,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$GILD Q1 total HepC sales $1.05 billion vs. $1.16 billion consensus.,es,[],[],[],0,3,13,[],['gild'],https://twitter.com/adamfeuerstein/status/991408464613269504,False,,0,,,,,,,,[],,,,
991399924255379456,991399924255379456,2018-05-02 01:02:15 IST,2018-05-02,01:02:15,+0530,14886375,stocktwits,Stocktwits,,You have less than 30 minutes. Here's who reports earnings TODAY after the market close:  ‚Ä¢ $AAPL ‚ùóÔ∏è ‚Ä¢ $SNAP  ‚Ä¢ $GILD ‚Ä¢ $GLUU ‚Ä¢ $TMUS ‚Ä¢ $FTR ‚Ä¢ $DVN ‚Ä¢ $SPPI ‚Ä¢ $TERP ‚Ä¢ $APC ‚Ä¢ $SU ‚Ä¢ $JNPR   https://t.co/BrJnctSA18,en,[],['https://stocktwits.com/discover/earnings-calendar'],[],0,16,37,[],"['aapl', 'snap', 'gild', 'gluu', 'tmus', 'ftr', 'dvn', 'sppi', 'terp', 'apc', 'su', 'jnpr']",https://twitter.com/Stocktwits/status/991399924255379456,False,,0,,,,,,,,[],,,,
991262539223896064,991262539223896064,2018-05-01 15:56:20 IST,2018-05-01,15:56:20,+0530,102754598,johncendpts,John Carroll,,Gilead joins the lineup of big biopharma partners to ally with Verily ‚Äî this time focused on immunology $GILD  https://t.co/austsLDo3T,en,[],['https://endpts.com/gilead-joins-the-lineup-of-big-biopharma-partners-to-ally-with-verily-this-time-focused-on-immunology/'],[],0,1,8,[],['gild'],https://twitter.com/JohnCendpts/status/991262539223896064,False,,0,,,,,,,,[],,,,
990713367433240576,990713367433240576,2018-04-30 03:34:08 IST,2018-04-30,03:34:08,+0530,14886375,stocktwits,Stocktwits,,Here‚Äôs who reports earnings this week:  Mon - $MCD $AKS $RIG $AGN $AKAM $FDC Tue - $AAPL $SNAP $GILD $SHOP $PFE $BP $MRK $UA Wed - $TSLA $FEYE $SQ $DDD $FIT $CHK $CVS $MRO $SSYS Thu - $GPRO $ATVI $CARA $TEVA $P $AA $SRPT $OSTK Fri - $AMD $BABA $CELG   https://t.co/uSdZZVvSRQ,en,[],['https://stocktwits.com/discover/earnings-calendar/2018-04-30'],[],8,51,121,[],"['mcd', 'aks', 'rig', 'agn', 'akam', 'fdc', 'aapl', 'snap', 'gild', 'shop', 'pfe', 'bp', 'mrk', 'ua', 'tsla', 'feye', 'sq', 'ddd', 'fit', 'chk', 'cvs', 'mro', 'ssys', 'gpro', 'atvi', 'cara', 'teva', 'p', 'aa', 'srpt', 'ostk', 'amd', 'baba', 'celg']",https://twitter.com/Stocktwits/status/990713367433240576,False,,0,,,,,,,,[],,,,
990655202318577664,990655202318577664,2018-04-29 23:43:00 IST,2018-04-29,23:43:00,+0530,274233761,bradloncar,Brad Loncar,,Huge week of earnings coming up.  M: $AGN $NBIX T: $GILD $INCY $IRWD $MRK W: $EXEL $NVO $UTHR T: $ALNY $REGN $SAGE $SRPT F: $AGIO $CELG $IONS  The full list:  https://t.co/iMjW2l3E9A  https://t.co/fa6YYIzhOy,en,[],['http://www.loncarblog.com/april-30-earnings'],['https://pbs.twimg.com/media/Db6nPQMVQAAstIF.jpg'],1,20,42,[],"['agn', 'nbix', 'gild', 'incy', 'irwd', 'mrk', 'exel', 'nvo', 'uthr', 'alny', 'regn', 'sage', 'srpt', 'agio', 'celg', 'ions']",https://twitter.com/bradloncar/status/990655202318577664,False,,1,https://pbs.twimg.com/media/Db6nPQMVQAAstIF.jpg,,,,,,,[],,,,
988820306562289665,988820306562289665,2018-04-24 22:11:47 IST,2018-04-24,22:11:47,+0530,873399943,jacobplieth,Jacob Plieth,,$NVS just confirmed to me that it filed Kymriah in Japan for both ped ALL and DLBCL $GILD $CELG cc @BLLPHD @cells_nnm,en,"[{'screen_name': 'bllphd', 'name': 'bruce levine, ph.d.', 'id': '211353183'}, {'screen_name': 'cells_nnm', 'name': 'alexey bersenev', 'id': '14063950'}]",[],[],0,9,10,[],"['nvs', 'gild', 'celg']",https://twitter.com/JacobPlieth/status/988820306562289665,False,,0,,,,,,,,[],,,,
986699335273459712,986699335273459712,2018-04-19 01:43:48 IST,2018-04-19,01:43:48,+0530,274233761,bradloncar,Brad Loncar,,"The Goldman note from the other day about ""is it better to develop things that aren't cures"" is the dumbest thing I've heard in a long time (for many reasons). Or at least how it is being interpreted by some.  $GILD paid $11B for $VRUS and so far sales are $54B+.",en,[],[],[],11,41,130,[],"['gild', 'vrus']",https://twitter.com/bradloncar/status/986699335273459712,False,,0,,,,,,,,[],,,,
986697699973042178,955452028469198848,2018-04-19 01:37:18 IST,2018-04-19,01:37:18,+0530,274233761,bradloncar,Brad Loncar,,@Mazmasta @AdamSinger $GILD acquisition of $VRUS will likely go down as the most successful acquisition in biotech history. What more do investors want? They paid $11B and sales so far have been $56B+. People (Goldman) who call that disappointing have no clue what they are talking about.,en,[],[],[],4,4,23,[],"['gild', 'vrus']",https://twitter.com/bradloncar/status/986697699973042178,False,,0,,,,,,,,"[{'screen_name': 'Mazmasta', 'name': 'E B', 'id': '27162339'}, {'screen_name': 'AdamSinger', 'name': 'Adam Singer', 'id': '14031032'}]",,,,
984067542229704707,984067542229704707,2018-04-11 19:25:59 IST,2018-04-11,19:25:59,+0530,6810242,bydavidcrow,David Crow,,"Wealthy Chinese often travel to US for healthcare, but rare to hear of someone going other way: Craig Chase's remarkable story of how his myeloma was cured by a 'Made in China' cell therapy  https://t.co/ZwGgfCcNHi $JNJ $CELG $BLUE $CLLS $NVS $GILD  https://t.co/CKHSeIcdm2",en,[],['https://www.ft.com/content/30b5a944-3b57-11e8-b9f9-de94fa33a81e'],['https://pbs.twimg.com/media/DagcIDfW0AEyGM7.jpg'],5,41,85,[],"['jnj', 'celg', 'blue', 'clls', 'nvs', 'gild']",https://twitter.com/bydavidcrow/status/984067542229704707,False,,1,https://pbs.twimg.com/media/DagcIDfW0AEyGM7.jpg,,,,,,,[],,,,
984049565547589633,984049565547589633,2018-04-11 18:14:33 IST,2018-04-11,18:14:33,+0530,6810242,bydavidcrow,David Crow,,Novartis CEO @VasNarasimhan explains why his company could turn to China to help manufacture its Car-T treatments: our Big Read on why the Chinese cell therapy revolution is real. $NVS $GILD $CELG  https://t.co/ZwGgfCcNHi  https://t.co/dqSLejaDor,en,"[{'screen_name': 'vasnarasimhan', 'name': 'vas narasimhan', 'id': '723488741348782080'}]",['https://www.ft.com/content/30b5a944-3b57-11e8-b9f9-de94fa33a81e'],['https://pbs.twimg.com/media/DagLz8rUMAAPA7e.jpg'],0,10,12,[],"['nvs', 'gild', 'celg']",https://twitter.com/bydavidcrow/status/984049565547589633,False,,1,https://pbs.twimg.com/media/DagLz8rUMAAPA7e.jpg,,,,,,,[],,,,
983319346868080640,983319346868080640,2018-04-09 17:52:56 IST,2018-04-09,17:52:56,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"At our breakfast, Gov. Charlie Baker lauds $VRTX for pursuing cystic fibrosis therapies, says cost is justified. Criticizes $GILD for HepC pricing.",en,[],[],[],5,6,8,[],"['vrtx', 'gild']",https://twitter.com/adamfeuerstein/status/983319346868080640,False,,0,,,,,,,,[],,,,
981182247146524674,981182247146524674,2018-04-03 20:20:51 IST,2018-04-03,20:20:51,+0530,873399943,jacobplieth,Jacob Plieth,,"$PFE says goodbye (but not quite farewell) to $CLLS. My take on Allogene and CAR-T's A-team, via @EPVantage  https://t.co/YngoUK62No $GILD $CELG $NVS",en,"[{'screen_name': 'epvantage', 'name': 'vantage', 'id': '841963175729856512'}]",['http://www.epvantage.com/Universal/View.aspx?type=Story&id=777431&isEPVantage=yes'],[],7,25,32,[],"['pfe', 'clls', 'gild', 'celg', 'nvs']",https://twitter.com/JacobPlieth/status/981182247146524674,False,,0,,,,,,,,[],,,,
981169590871797760,981166176456921088,2018-04-03 19:30:34 IST,2018-04-03,19:30:34,+0530,873399943,jacobplieth,Jacob Plieth,,"@zbiotech @dsobek Remember those assurances that key $KITE leaders would stay with $GILD after the takeover? How's that working out, I wonder.",en,[],[],[],2,1,7,[],"['kite', 'gild']",https://twitter.com/JacobPlieth/status/981169590871797760,False,,0,,,,,,,,"[{'screen_name': 'zbiotech', 'name': 'zach', 'id': '19717430'}, {'screen_name': 'dsobek', 'name': 'David Sobek', 'id': '243801041'}]",,,,
981152506289025024,981152506289025024,2018-04-03 18:22:41 IST,2018-04-03,18:22:41,+0530,47678782,megtirrell,Meg Tirrell,,"After selling $KITE to $GILD for $11B, Belldegrun and Chang point out its shortfalls and found new company to address them (from @matthewherper):  https://t.co/V1oUpPbAgf  https://t.co/zP7Bn1vQAa",en,"[{'screen_name': 'matthewherper', 'name': 'matthew herper', 'id': '44438256'}]",['https://www.forbes.com/sites/matthewherper/2018/04/03/raising-300-million-kite-execs-partner-with-pfizer-to-disrupt-their-last-cancer-treatment/#6e8deddc32a2'],['https://pbs.twimg.com/media/DZ3BADeUQAAqTv7.jpg'],8,18,41,[],"['kite', 'gild']",https://twitter.com/megtirrell/status/981152506289025024,False,,1,https://pbs.twimg.com/media/DZ3BADeUQAAqTv7.jpg,,,,,,,[],,,,
981147392010579968,981139851247529989,2018-04-03 18:02:21 IST,2018-04-03,18:02:21,+0530,873399943,jacobplieth,Jacob Plieth,,"Allogene among biggest seed/series A rounds. $JUNO 's was $120m, $ADAP $104m, Tmunity $100m. $KITE $GILD $CELG $CLLS  https://t.co/jgfnphFoCV",en,[],[],['https://pbs.twimg.com/media/DZ28PZIXcAAA5k1.jpg'],1,7,10,[],"['juno', 'adap', 'kite', 'gild', 'celg', 'clls']",https://twitter.com/JacobPlieth/status/981147392010579968,False,,1,https://pbs.twimg.com/media/DZ28PZIXcAAA5k1.jpg,,,,,,,[],,,,
981145776616329216,981139851247529989,2018-04-03 17:55:56 IST,2018-04-03,17:55:56,+0530,873399943,jacobplieth,Jacob Plieth,,Back in Nov 2016 I spoke to Arie B &amp; David Chang about $CLLS and allogeneic CARs. $KITE $GILD  https://t.co/9gz9ZWZIVl,en,[],[],['https://pbs.twimg.com/media/DZ262bUXkAA_gdy.jpg'],3,1,12,[],"['clls', 'kite', 'gild']",https://twitter.com/JacobPlieth/status/981145776616329216,False,,1,https://pbs.twimg.com/media/DZ262bUXkAA_gdy.jpg,,,,,,,[],,,,
978413803867123712,978413803867123712,2018-03-27 05:00:03 IST,2018-03-27,05:00:03,+0530,102754598,johncendpts,John Carroll,,Revenue down? No worries for Gilead CEO Milligan as compensation swells to $15.4M $GILD $PFE etc  https://t.co/UpQo9FboKo,en,[],['https://endpts.com/revenue-down-no-worries-for-gilead-ceo-milligan-as-compensation-swells-to-15-4m/'],[],3,5,7,[],"['gild', 'pfe']",https://twitter.com/JohnCendpts/status/978413803867123712,False,,0,,,,,,,,[],,,,
977197746112299008,902928283771297792,2018-03-23 20:27:52 IST,2018-03-23,20:27:52,+0530,873399943,jacobplieth,Jacob Plieth,,Final ICER report on CAR-T pricing:  https://t.co/sD6PLX4h5H $NVS $CELG $GILD,en,[],['https://icer-review.org/wp-content/uploads/2017/07/ICER_CAR_T_Final_Evidence_Report_032318.pdf'],[],0,4,7,[],"['nvs', 'celg', 'gild']",https://twitter.com/JacobPlieth/status/977197746112299008,False,,0,,,,,,,,[],,,,
976918275069267968,976918275069267968,2018-03-23 01:57:21 IST,2018-03-23,01:57:21,+0530,14292717,petenajarian,Pete Najarian,,Najarian Brothers Make Final Trades in $AA &amp; $GILD  https://t.co/AXrIPBTAuq via @investitute,en,"[{'screen_name': 'investitute', 'name': 'investitute', 'id': '1295683179412512768'}]",['http://zpr.io/nhcE5'],[],1,1,6,[],"['aa', 'gild']",https://twitter.com/petenajarian/status/976918275069267968,False,,0,,,,,,,,[],,,,
974647799223595008,974647799223595008,2018-03-16 19:35:18 IST,2018-03-16,19:35:18,+0530,15568127,themotleyfool,The Motley Fool,,Fascinating news on the HIV treatment front out of $GILD.  https://t.co/XqJKULkoV8,en,[],['https://www.fool.com/investing/2018/03/14/is-gilead-sciences-trying-to-put-itself-out-of-bus.aspx'],[],1,2,10,[],['gild'],https://twitter.com/themotleyfool/status/974647799223595008,False,,0,,,,,,,,[],,,,
973272907249082370,973272907249082370,2018-03-13 00:31:58 IST,2018-03-13,00:31:58,+0530,102754598,johncendpts,John Carroll,,"One of the best R&amp;D groups in terms of execution -- Gilead R&amp;D chief Norbert Bischofberger is leaving in surprise exit, CEO revamps top science jobs $GILD  https://t.co/mgmmZIYhSv",en,[],['https://endpts.com/gilead-rd-chief-norbert-bischofberger-is-leaving-in-surprise-exit-ceo-revamps-top-science-jobs/'],[],4,3,9,[],['gild'],https://twitter.com/JohnCendpts/status/973272907249082370,False,,0,,,,,,,,[],,,,
973248066512973826,973248066512973826,2018-03-12 22:53:15 IST,2018-03-12,22:53:15,+0530,102094857,adamfeuerstein,Adam Feuerstein,,End of an era: Gilead‚Äôs longtime R&amp;D chief is stepping down at a pivotal moment for the company  https://t.co/eQ2q3UOvkL via @RebeccaDRobbins $GILD,en,"[{'screen_name': 'rebeccadrobbins', 'name': 'rebecca robbins', 'id': '368158573'}]",['https://www.statnews.com/2018/03/12/gilead-bischofberger/'],[],0,5,10,[],['gild'],https://twitter.com/adamfeuerstein/status/973248066512973826,False,,0,,,,,,,,[],,,,
973189420697489408,973189420697489408,2018-03-12 19:00:13 IST,2018-03-12,19:00:13,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Big shakeup. $GILD  https://t.co/ZW0s5ThcCf,en,[],['https://twitter.com/gileadsciences/status/973183192772395008'],[],2,7,9,[],['gild'],https://twitter.com/adamfeuerstein/status/973189420697489408,False,https://twitter.com/gileadsciences/status/973183192772395008,0,,,,,,,,[],,,,
971032472837349376,971032472837349376,2018-03-06 20:09:17 IST,2018-03-06,20:09:17,+0530,56413858,foxbusiness,FOX Business,,#StockAlert: S&amp;P 500 winners $MYL $NVDA $LRCX $GILD $AVGO  https://t.co/NZuJKVX3cs  https://t.co/aDBH4rJHwR,sv,[],['http://fxn.ws/2tkf2Zp'],['https://pbs.twimg.com/media/DXnMvcrXUAEz6r8.jpg'],0,4,10,['stockalert'],"['myl', 'nvda', 'lrcx', 'gild', 'avgo']",https://twitter.com/FoxBusiness/status/971032472837349376,False,,1,https://pbs.twimg.com/media/DXnMvcrXUAEz6r8.jpg,,,,,,,[],,,,
971026145373286405,971026145373286405,2018-03-06 19:44:08 IST,2018-03-06,19:44:08,+0530,102754598,johncendpts,John Carroll,,"Searching for HIV cure, Gilead‚Äôs new ‚Äòshock and kill‚Äô combo swats back lethal virus in monkeys $GILD  https://t.co/4kTAPVCm2G",en,[],['https://endpts.com/searching-for-hiv-cure-harvard-team-marks-the-success-of-gileads-new-shock-and-kill-combo-in-monkeys/'],[],1,5,7,[],['gild'],https://twitter.com/JohnCendpts/status/971026145373286405,False,,0,,,,,,,,[],,,,
970783608616124417,931159713542213634,2018-03-06 03:40:23 IST,2018-03-06,03:40:23,+0530,873399943,jacobplieth,Jacob Plieth,,Autolus files for potential US IPO  https://t.co/fwFmlupppW $CELG $BLUE $GILD $CLLS,en,[],['https://www.autolus.com/news-and-events/press-releases/autolus-announces-confidential-submission-draft-registration-statement-potential-initial-public-offering-united-states'],[],3,10,17,[],"['celg', 'blue', 'gild', 'clls']",https://twitter.com/JacobPlieth/status/970783608616124417,False,,0,,,,,,,,[],,,,
967934270332260352,967934270332260352,2018-02-26 06:58:08 IST,2018-02-26,06:58:08,+0530,100024370,ophirgottlieb,Ophir Gottlieb,,In focus: $AAPL $GOOGL $MSFT $GILD $DIS  Yes. A volatile market can be a once in a generation opportunity.  Now is that time.  We discuss it in detail here:   https://t.co/8fR5jgnkEs,en,[],['https://vimeo.com/255317960'],[],1,2,7,[],"['aapl', 'googl', 'msft', 'gild', 'dis']",https://twitter.com/OphirGottlieb/status/967934270332260352,False,,0,,,,,,,,[],,,,
967385716643827717,967385716643827717,2018-02-24 18:38:22 IST,2018-02-24,18:38:22,+0530,102754598,johncendpts,John Carroll,,Top 5 for the week: #1 - the gene editing surprise -- All in: Gilead maps a $3.15B gene editing alliance with Sangamo for off-the-shelf CAR-T drugs $GILD $SGMO   https://t.co/q2qfG1rmQZ,en,[],['https://endpts.com/all-in-gilead-maps-a-3-15b-alliance-with-sangamo-for-off-the-shelf-car-t-drugs/'],[],1,12,21,[],"['gild', 'sgmo']",https://twitter.com/JohnCendpts/status/967385716643827717,False,,0,,,,,,,,[],,,,
966654092767580160,966647917296717825,2018-02-22 18:11:09 IST,2018-02-22,18:11:09,+0530,873399943,jacobplieth,Jacob Plieth,,Quick list of genome-editing technologies/deals with a specific cell therapy focus. Am I missing any? $CELG $GILD $NVS $JUNO $KITE $SGMO  https://t.co/DfrHGRvoUG,en,[],[],['https://pbs.twimg.com/media/DWo-v7NX0AE6jc4.jpg'],4,12,21,[],"['celg', 'gild', 'nvs', 'juno', 'kite', 'sgmo']",https://twitter.com/JacobPlieth/status/966654092767580160,False,,1,https://pbs.twimg.com/media/DWo-v7NX0AE6jc4.jpg,,,,,,,[],,,,
966650801438576641,966650801438576641,2018-02-22 17:58:05 IST,2018-02-22,17:58:05,+0530,102754598,johncendpts,John Carroll,,All in: Gilead maps a $3.15B gene editing alliance with Sangamo for off-the-shelf CAR-T drugs $GILD $CELG $NVS  https://t.co/q2qfG1rmQZ,en,[],['https://endpts.com/all-in-gilead-maps-a-3-15b-alliance-with-sangamo-for-off-the-shelf-car-t-drugs/'],[],3,22,48,[],"['gild', 'celg', 'nvs']",https://twitter.com/JohnCendpts/status/966650801438576641,False,,0,,,,,,,,[],,,,
966647917296717825,966647917296717825,2018-02-22 17:46:37 IST,2018-02-22,17:46:37,+0530,873399943,jacobplieth,Jacob Plieth,,In CAR-T genome editing $NVS and $JUNO $CELG both went for Crispr. $KITE $GILD picks Zn finger nucleases $SGMO. Interesting move,en,[],[],[],7,27,44,[],"['nvs', 'juno', 'celg', 'kite', 'gild', 'sgmo']",https://twitter.com/JacobPlieth/status/966647917296717825,False,,0,,,,,,,,[],,,,
966645180429488128,966645180429488128,2018-02-22 17:35:45 IST,2018-02-22,17:35:45,+0530,102094857,adamfeuerstein,Adam Feuerstein,,The timing of the $SGMO $GILD pact is perfect for our genome editing webinar at 1pm ET today. We'll discuss.,en,[],[],[],1,1,15,[],"['sgmo', 'gild']",https://twitter.com/adamfeuerstein/status/966645180429488128,False,,0,,,,,,,,[],,,,
966277212944125952,966277212944125952,2018-02-21 17:13:34 IST,2018-02-21,17:13:34,+0530,102754598,johncendpts,John Carroll,,The top 15 R&amp;D spenders in global drug R&amp;D ‚Äî late-stage profiles on: $RHHBY $MRK $NVS $JNJ $PFE $SNY $BMY $GSK $CELG $AZN $LLY $ABBV $GILD $AMGN Takeda  https://t.co/Lyqki5kDXQ,en,[],['https://endpts.com/the-good-the-bad-and-the-ugly-for-the-top-15-spenders-in-the-global-drug-rd-business-2018/'],[],0,7,11,[],"['rhhby', 'mrk', 'nvs', 'jnj', 'pfe', 'sny', 'bmy', 'gsk', 'celg', 'azn', 'lly', 'abbv', 'gild', 'amgn']",https://twitter.com/JohnCendpts/status/966277212944125952,False,,0,,,,,,,,[],,,,
964984087088832512,964984087088832512,2018-02-18 03:35:09 IST,2018-02-18,03:35:09,+0530,100024370,ophirgottlieb,Ophir Gottlieb,,In focus: $AAPL $GOOGL $MSFT $GILD $DIS $NVDA  Yes. A volatile market can be a once in a generation opportunity.  Now is that time.  We discuss it in detail here:   https://t.co/AaReypoiiG  https://t.co/CvTmU8KKYU,en,[],['https://zoom.us/webinar/register/WN_pNmPzfy4RZ6-OZJ9AhS41A'],['https://pbs.twimg.com/media/DWRP25vU0AAbpSy.jpg'],1,7,10,[],"['aapl', 'googl', 'msft', 'gild', 'dis', 'nvda']",https://twitter.com/OphirGottlieb/status/964984087088832512,False,,1,https://pbs.twimg.com/media/DWRP25vU0AAbpSy.jpg,,,,,,,[],,,,
961829950440394754,961829950440394754,2018-02-09 10:41:44 IST,2018-02-09,10:41:44,+0530,14071129,paulkidd,Paul Kidd,,The #PBAC decision on #PrEP was that it should be listed if the price per patient was $2500/year ($208/mth) or less. Presumably the sponsors (which include $GILD and two generic manufacturers) have agreed to that price.  https://t.co/zg3rvpO78G,en,[],[],"['https://pbs.twimg.com/media/DVkbMJ8U8AUNx3m.jpg', 'https://pbs.twimg.com/media/DVkbMN1VwAE6Nul.jpg']",1,1,9,"['pbac', 'prep']",['gild'],https://twitter.com/paulkidd/status/961829950440394754,False,,1,https://pbs.twimg.com/media/DVkbMJ8U8AUNx3m.jpg,,,,,,,[],,,,
961560968550592512,961560968550592512,2018-02-08 16:52:54 IST,2018-02-08,16:52:54,+0530,102754598,johncendpts,John Carroll,,No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging -- files suit against $GILD -- launches new PhIII targeting $GILD -- boosting R&amp;D spending -- gets lucky! $NVS gets CRL on generic Advair $GSK  https://t.co/Cru8TEvw2R,en,[],['https://endpts.com/no-more-mr-nice-guy-glaxosmithkline-is-coming-out-of-its-corner-swinging/'],[],2,14,26,[],"['gild', 'gild', 'nvs', 'gsk']",https://twitter.com/JohnCendpts/status/961560968550592512,False,,0,,,,,,,,[],,,,
961357080119607298,961357080119607298,2018-02-08 03:22:43 IST,2018-02-08,03:22:43,+0530,102754598,johncendpts,John Carroll,,$GSK files HIV patent suit -- UPDATED: Gilead gets a blockbuster boost from an FDA OK of HIV triplet Biktarvy ‚Äî and rival GSK fires back $GILD  https://t.co/4o9XoL7KO1,en,[],['https://endpts.com/with-hep-c-cash-dwindling-gilead-gets-a-blockbuster-boost-from-an-fda-ok-of-hiv-triplet-biktarvy/'],[],0,6,8,[],"['gsk', 'gild']",https://twitter.com/JohnCendpts/status/961357080119607298,False,,0,,,,,,,,[],,,,
961325676166082560,961325676166082560,2018-02-08 01:17:56 IST,2018-02-08,01:17:56,+0530,234905402,halftimereport,CNBC Halftime Report,,.@petenajarian &amp; @jonnajarian are seeing some ~unusual~ things in the options market...!  $PG $GILD   https://t.co/rthve2lrUo,en,"[{'screen_name': 'petenajarian', 'name': 'pete najarian', 'id': '14292717'}, {'screen_name': 'jonnajarian', 'name': 'jon najarian', 'id': '14115408'}]",['https://www.cnbc.com/video/2018/02/07/unusual-options-activity-procter-and-gamble-gilead.html'],[],3,4,18,[],"['pg', 'gild']",https://twitter.com/HalftimeReport/status/961325676166082560,False,,0,,,,,,,,[],,,,
961324525706194947,961324525706194947,2018-02-08 01:13:22 IST,2018-02-08,01:13:22,+0530,102754598,johncendpts,John Carroll,,"It's on! With hep C cash dwindling, Gilead gets a blockbuster boost from an FDA OK of HIV triplet Biktarvy $GILD $GSK  https://t.co/4o9XoL7KO1",en,[],['https://endpts.com/with-hep-c-cash-dwindling-gilead-gets-a-blockbuster-boost-from-an-fda-ok-of-hiv-triplet-biktarvy/'],[],1,2,10,[],"['gild', 'gsk']",https://twitter.com/JohnCendpts/status/961324525706194947,False,,0,,,,,,,,[],,,,
961215601548124160,961215601548124160,2018-02-07 18:00:32 IST,2018-02-07,18:00:32,+0530,102754598,johncendpts,John Carroll,,"J&amp;J antes up on a $1B gamble that Theravance has the next blockbuster JAK1 for Crohn‚Äôs, ulcerative colitis $TBPH $JNJ $GILD $ABBV  https://t.co/eO94rZH48O",en,[],['https://endpts.com/jj-antes-up-on-a-1b-gamble-that-theravance-has-the-next-blockbuster-jak1-for-crohns-ulcerative-colitis/'],[],1,8,11,[],"['tbph', 'jnj', 'gild', 'abbv']",https://twitter.com/JohnCendpts/status/961215601548124160,False,,0,,,,,,,,[],,,,
961199200192090113,961199200192090113,2018-02-07 16:55:22 IST,2018-02-07,16:55:22,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$GILD rips off the hepatitis C band-aid. From this morning's Readout.  https://t.co/1AO46qVpNs,en,[],[],"['https://pbs.twimg.com/media/DVbdkFSVMAEqOe0.jpg', 'https://pbs.twimg.com/media/DVbdkFRVQAA4lVE.jpg']",4,14,16,[],['gild'],https://twitter.com/adamfeuerstein/status/961199200192090113,False,,1,https://pbs.twimg.com/media/DVbdkFSVMAEqOe0.jpg,,,,,,,[],,,,
960995527096664064,960995527096664064,2018-02-07 03:26:02 IST,2018-02-07,03:26:02,+0530,47678782,megtirrell,Meg Tirrell,,"In NASH, rapid clinical trial enrollment has put $GILD in the lead for most severe form, CEO John Milligan says on conference call. With positive study readouts, could launch first NASH drug in 2020",en,[],[],[],4,17,29,[],['gild'],https://twitter.com/megtirrell/status/960995527096664064,False,,0,,,,,,,,[],,,,
960991085332975616,960991085332975616,2018-02-07 03:08:23 IST,2018-02-07,03:08:23,+0530,274233761,bradloncar,Brad Loncar,,Imagine how angry people would be if $GILD still hadn‚Äôt done a deal yet. You can see why so many big companies HAVE to get active and make up for slowing revenue growth.,en,[],[],[],4,10,33,[],['gild'],https://twitter.com/bradloncar/status/960991085332975616,False,,0,,,,,,,,[],,,,
960985824752996352,960985824752996352,2018-02-07 02:47:29 IST,2018-02-07,02:47:29,+0530,274233761,bradloncar,Brad Loncar,,$GILD HCV lifecycle.  https://t.co/aCsGROXNyO,en,[],[],['https://pbs.twimg.com/media/DVYbfVfVoAA2R0W.jpg'],6,16,29,[],['gild'],https://twitter.com/bradloncar/status/960985824752996352,False,,1,https://pbs.twimg.com/media/DVYbfVfVoAA2R0W.jpg,,,,,,,[],,,,
960985659581353985,960985659581353985,2018-02-07 02:46:50 IST,2018-02-07,02:46:50,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$GILD HepC product sales guidance for 2018 is $3.5 - 4 billion, or in other words, ripping the band-aid clear off.",en,[],[],[],3,8,16,[],['gild'],https://twitter.com/adamfeuerstein/status/960985659581353985,False,,0,,,,,,,,[],,,,
960983930987057153,960983930987057153,2018-02-07 02:39:58 IST,2018-02-07,02:39:58,+0530,102094857,adamfeuerstein,Adam Feuerstein,,$GILD does break out 2018 sales guidance by product in slide deck. Here ‚Äî&gt;  https://t.co/Pq37PPgTra,en,[],[],['https://pbs.twimg.com/media/DVYZw_-VAAA4ldI.jpg'],0,1,7,[],['gild'],https://twitter.com/adamfeuerstein/status/960983930987057153,False,,1,https://pbs.twimg.com/media/DVYZw_-VAAA4ldI.jpg,,,,,,,[],,,,
960983358347112448,960983358347112448,2018-02-07 02:37:41 IST,2018-02-07,02:37:41,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$GILD net product sales guidance for 2018: $20-21 billion. That‚Äôs on the low end of consensus $21.3 billion, although I believe buyside is  already more conservative. No breakout of product mix sales guidance in release.",en,[],[],[],0,2,8,[],['gild'],https://twitter.com/adamfeuerstein/status/960983358347112448,False,,0,,,,,,,,[],,,,
960975556220194816,960975556220194816,2018-02-07 02:06:41 IST,2018-02-07,02:06:41,+0530,14886375,stocktwits,Stocktwits,,"Ladies and gentlemen, get ready. All of these companies are reporting earnings TODAY at 4 PM ET:  ‚Ä¢ $SNAP  üëª ‚Ä¢ $DIS  üê≠ ‚Ä¢ $GILD  üåØ ‚Ä¢ $CMG ‚Ä¢ $MTCH ‚Ä¢ $AKAM ‚Ä¢ $APC ‚Ä¢ $PXD ‚Ä¢ $PAYC ‚Ä¢ $ZEN ‚Ä¢ $MYGN ‚Ä¢ $NEWR ‚Ä¢ $TCS   https://t.co/BrJnctSA18",en,[],['https://stocktwits.com/discover/earnings-calendar'],[],1,15,39,[],"['snap', 'dis', 'gild', 'cmg', 'mtch', 'akam', 'apc', 'pxd', 'payc', 'zen', 'mygn', 'newr', 'tcs']",https://twitter.com/Stocktwits/status/960975556220194816,False,,0,,,,,,,,[],,,,
960970239767990272,960970239767990272,2018-02-07 01:45:33 IST,2018-02-07,01:45:33,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Reminder: $GILD earnings after the close.,en,[],[],[],5,2,13,[],['gild'],https://twitter.com/adamfeuerstein/status/960970239767990272,False,,0,,,,,,,,[],,,,
960226450027638784,960226450027638784,2018-02-05 00:30:00 IST,2018-02-05,00:30:00,+0530,274233761,bradloncar,Brad Loncar,,Another big week of earnings ahead:  M: $BMY $GWPH T: $AGN $GILD $SGEN W: $GSK $SNY T: $ALXN $ALNY $REGN F: $ARWR $IMGN  The full schedule:  https://t.co/jO962XXs2q  https://t.co/LrPkuTiIuu,en,[],['http://www.loncarblog.com/february-5-earnings'],['https://pbs.twimg.com/media/DVFt9CwVMAEWLfw.jpg'],2,16,34,[],"['bmy', 'gwph', 'agn', 'gild', 'sgen', 'gsk', 'sny', 'alxn', 'alny', 'regn', 'arwr', 'imgn']",https://twitter.com/bradloncar/status/960226450027638784,False,,1,https://pbs.twimg.com/media/DVFt9CwVMAEWLfw.jpg,,,,,,,[],,,,
958826483769856000,958826483769856000,2018-02-01 03:47:02 IST,2018-02-01,03:47:02,+0530,274233761,bradloncar,Brad Loncar,,"Just as with the $GILD ZUMA-1 update at #ASH17, it's very meaningful to see $NVS CAR-T in pediatric ALL stay durable over longer periods of time. These treatments have been developed so quickly that we honestly didn't know for sure. Now you are starting to see it.",en,[],[],[],2,12,36,['ash17'],"['gild', 'nvs']",https://twitter.com/bradloncar/status/958826483769856000,False,,0,,,,,,,,[],,,,
956910541544534016,956910541544534016,2018-01-26 20:53:46 IST,2018-01-26,20:53:46,+0530,39853973,timseymour,Tim Seymour,,$GILD out of jail! $IBB   BOOM,en,[],[],[],5,3,17,[],"['gild', 'ibb']",https://twitter.com/timseymour/status/956910541544534016,False,,0,,,,,,,,[],,,,
956161127842398208,956161127842398208,2018-01-24 19:15:52 IST,2018-01-24,19:15:52,+0530,873399943,jacobplieth,Jacob Plieth,,"The threat to $NVS CAR-T 2.0 just got real. My take on Tmunity, via @EPVantage  https://t.co/8sx340IpGO $GILD $CELG $CRSP",en,"[{'screen_name': 'epvantage', 'name': 'vantage', 'id': '841963175729856512'}]",['http://bit.ly/2DCr5Gk'],[],6,23,36,[],"['nvs', 'gild', 'celg', 'crsp']",https://twitter.com/JacobPlieth/status/956161127842398208,False,,0,,,,,,,,[],,,,
956117701306601472,956117701306601472,2018-01-24 16:23:18 IST,2018-01-24,16:23:18,+0530,873399943,jacobplieth,Jacob Plieth,,"$NVS Vas Narasimhan just said ICER had given its backing to CAR-T therapy pricing. As @ByJonGardner pointed out, it's a bit more complicated:  https://t.co/03pcXYQslp $GILD $CELG",en,"[{'screen_name': 'byjongardner', 'name': 'jon gardner', 'id': '960747870'}]",['http://epvantage.com/Universal/View.aspx?type=Story&id=756630&isEPVantage=yes'],[],0,5,7,[],"['nvs', 'gild', 'celg']",https://twitter.com/JacobPlieth/status/956117701306601472,False,,0,,,,,,,,[],,,,
955836882092511232,955836882092511232,2018-01-23 21:47:25 IST,2018-01-23,21:47:25,+0530,873399943,jacobplieth,Jacob Plieth,,Carl June's Tmunity just raised $100m from investors including... $GILD ! (No mention of $NVS )  https://t.co/GeIlWcTrE6,en,[],['http://bit.ly/2DAoHjm'],[],1,9,15,[],"['gild', 'nvs']",https://twitter.com/JacobPlieth/status/955836882092511232,False,,0,,,,,,,,[],,,,
955410197069090816,955410197069090816,2018-01-22 17:31:56 IST,2018-01-22,17:31:56,+0530,102754598,johncendpts,John Carroll,,Here's an obvious prediction -- $CELG and $GILD will duke it out over next-gen CAR-T tech. With $NVS picking things off selectively,en,[],[],[],3,3,14,[],"['celg', 'gild', 'nvs']",https://twitter.com/JohnCendpts/status/955410197069090816,False,,0,,,,,,,,[],,,,
955405501826727938,955405501826727938,2018-01-22 17:13:16 IST,2018-01-22,17:13:16,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"$CELG buying $JUNO is smart if you believe in the long-term future of CAR-T, particularly in blood-related cancer. $CELG strategy same as $GILD ‚Äî Need to own this.",en,[],[],[],8,14,60,[],"['celg', 'juno', 'celg', 'gild']",https://twitter.com/adamfeuerstein/status/955405501826727938,False,,0,,,,,,,,[],,,,
953997541225443329,953997541225443329,2018-01-18 19:58:32 IST,2018-01-18,19:58:32,+0530,102754598,johncendpts,John Carroll,,"Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo $GILD $PFE $NVS  https://t.co/BRhOcZzFd3",en,[],['https://endpts.com/beefing-up-its-car-t-pipeline-gilead-teams-up-with-pfizer-on-a-lymphoma-combo/'],[],0,2,11,[],"['gild', 'pfe', 'nvs']",https://twitter.com/JohnCendpts/status/953997541225443329,False,,0,,,,,,,,[],,,,
953587548437319680,953587548437319680,2018-01-17 16:49:23 IST,2018-01-17,16:49:23,+0530,102754598,johncendpts,John Carroll,,Kymriah gets speed reviews in US and EU as Novartis looks to swiftly expand CAR-T indications $NVS $GILD @AmberTongPW  https://t.co/ywa3it5ZGP,en,"[{'screen_name': 'ambertongpw', 'name': 'amber tong', 'id': '746441781588426752'}]",['https://endpts.com/kymriah-gets-speed-reviews-in-us-and-eu-as-novartis-looks-to-swiftly-expand-car-t-indications/'],[],0,2,8,[],"['nvs', 'gild']",https://twitter.com/JohnCendpts/status/953587548437319680,False,,0,,,,,,,,[],,,,
951280072283115520,951280072283115520,2018-01-11 08:00:17 IST,2018-01-11,08:00:17,+0530,15568127,themotleyfool,The Motley Fool,,"Healthcare companies as a group just keep raking in the cash. If you can‚Äôt beat ‚Äòem, you might want to join ‚Äòem. $BMY $GILD $CELG  https://t.co/Nb38gdZtQ6",en,[],['https://www.fool.com/investing/2018/01/09/3-top-healthcare-stocks-to-buy-in-january.aspx'],[],1,5,37,[],"['bmy', 'gild', 'celg']",https://twitter.com/themotleyfool/status/951280072283115520,False,,0,,,,,,,,[],,,,
950851052265287680,950851052265287680,2018-01-10 03:35:31 IST,2018-01-10,03:35:31,+0530,370238655,jodigralnick,jodi gralnick,,"ICYMI: $GILD @GileadSciences CEO John Milligan talks EXCLUSIVELY to @megtirrell at $JPM18 about M&amp;A, drug pricing, Hep C and CAR-T:  https://t.co/slDja9PhtJ @CNBCnow @CNBCClosingBell",en,"[{'screen_name': 'gileadsciences', 'name': 'gilead sciences', 'id': '309728693'}, {'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}, {'screen_name': 'cnbcnow', 'name': 'cnbc now', 'id': '26574283'}, {'screen_name': 'cnbcclosingbell', 'name': ""cnbc's closing bell"", 'id': '21778391'}]",['http://cnb.cx/2CMaHhJ'],[],0,9,15,[],['gild'],https://twitter.com/jodigralnick/status/950851052265287680,False,,0,,,,,,,,[],,,,
950822105079209984,950822105079209984,2018-01-10 01:40:29 IST,2018-01-10,01:40:29,+0530,47678782,megtirrell,Meg Tirrell,,Coming up from #JPM18 on @CNBCClosingBell: $GILD CEO John Milligan. Points for anyone who can identify the appropriate theme of his tie!  https://t.co/GUS9A9tXQT,en,"[{'screen_name': 'cnbcclosingbell', 'name': ""cnbc's closing bell"", 'id': '21778391'}]",[],['https://pbs.twimg.com/media/DTH_qk5VAAEPdr2.jpg'],14,3,24,['jpm18'],['gild'],https://twitter.com/megtirrell/status/950822105079209984,False,,1,https://pbs.twimg.com/media/DTH_qk5VAAEPdr2.jpg,,,,,,,[],,,,
950502385222381568,950502385222381568,2018-01-09 04:30:02 IST,2018-01-09,04:30:02,+0530,370238655,jodigralnick,jodi gralnick,,"That's a wrap for day 1 of #JPM18 tomorrow: CEOs of $ILMN, $JNJ, $VRX, $GILD, $REGN join @megtirrell for EXCLUSIVE interviews on @CNBC @CNBCnow",en,"[{'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}, {'screen_name': 'cnbc', 'name': 'cnbc', 'id': '20402945'}, {'screen_name': 'cnbcnow', 'name': 'cnbc now', 'id': '26574283'}]",[],[],0,3,13,['jpm18'],"['ilmn', 'jnj', 'vrx', 'gild', 'regn']",https://twitter.com/jodigralnick/status/950502385222381568,False,,0,,,,,,,,[],,,,
950074974110281728,950074974110281728,2018-01-08 00:11:40 IST,2018-01-08,00:11:40,+0530,370238655,jodigralnick,jodi gralnick,,"#JPM18 starts tomorrow and @CNBCnow has you covered! @megtirrell LIVE w/ CEOs of $BIIB $LLY $GSK $EDIT $MRK $ILMN $JNJ $FOLD $GILD $REGN Monday &amp; Tuesday, plus more, starting @SquawkCNBC tomorrow 830amET w @biogen EXCLUSIVE.  https://t.co/1PUx61GQKF",en,"[{'screen_name': 'cnbcnow', 'name': 'cnbc now', 'id': '26574283'}, {'screen_name': 'megtirrell', 'name': 'meg tirrell', 'id': '47678782'}, {'screen_name': 'squawkcnbc', 'name': 'squawk box', 'id': '404422077'}, {'screen_name': 'biogen', 'name': 'biogen', 'id': '155650832'}]",[],['https://pbs.twimg.com/media/DS9YJifUMAAqIdr.jpg'],0,28,24,['jpm18'],"['biib', 'lly', 'gsk', 'edit', 'mrk', 'ilmn', 'jnj', 'fold', 'gild', 'regn']",https://twitter.com/jodigralnick/status/950074974110281728,False,,1,https://pbs.twimg.com/media/DS9YJifUMAAqIdr.jpg,,,,,,,[],,,,
949387702318845952,949387702318845952,2018-01-06 02:40:41 IST,2018-01-06,02:40:41,+0530,370238655,jodigralnick,jodi gralnick,,"Before you go off for the weekend, check out our kinda impressive lineup (if I may say so) for #JPM18 on @CNBCnow. Tune in all day Monday and Tuesday:  $BIIB, $LLY, $GSK, $EDIT, $MRK, $ILMN, $JNJ, $FOLD, $VRX, $GILD, $REGN and more!  https://t.co/PnzgDW9hlG",en,"[{'screen_name': 'cnbcnow', 'name': 'cnbc now', 'id': '26574283'}]",[],['https://pbs.twimg.com/media/DSznEwwUMAARwM-.jpg'],0,4,20,['jpm18'],"['biib', 'lly', 'gsk', 'edit', 'mrk', 'ilmn', 'jnj', 'fold', 'vrx', 'gild', 'regn']",https://twitter.com/jodigralnick/status/949387702318845952,False,,1,https://pbs.twimg.com/media/DSznEwwUMAARwM-.jpg,,,,,,,[],,,,
949354070619324416,949353287932891137,2018-01-06 00:27:03 IST,2018-01-06,00:27:03,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Oh, and to the guy in the $GILD breakout session last year who looked at me with disgust bc I wasn‚Äôt wearing a jacket/blazer: I‚Äôm still not. Sorry, not sorry.",en,[],[],[],3,0,20,[],['gild'],https://twitter.com/adamfeuerstein/status/949354070619324416,False,,0,,,,,,,,[],,,,
949295909850042368,949295909850042368,2018-01-05 20:35:56 IST,2018-01-05,20:35:56,+0530,873399943,jacobplieth,Jacob Plieth,,"ICER looks to have endorsed CAR-T pricing, but the truth is more complicated. Via @ByJonGardner  https://t.co/03pcXYQslp $NVS $GILD $JUNO $CELG $BLUE",en,"[{'screen_name': 'byjongardner', 'name': 'jon gardner', 'id': '960747870'}]",['http://epvantage.com/Universal/View.aspx?type=Story&id=756630&isEPVantage=yes'],[],1,5,10,[],"['nvs', 'gild', 'juno', 'celg', 'blue']",https://twitter.com/JacobPlieth/status/949295909850042368,False,,0,,,,,,,,[],,,,
948962522878660610,948869866928463873,2018-01-04 22:31:10 IST,2018-01-04,22:31:10,+0530,873399943,jacobplieth,Jacob Plieth,,"Interestingly, reimbursement doesn't seem to be a hurdle for commercial CAR-T therapy, Joshua Brody says (involved in Yescarta $GILD for DLBCL)",en,[],[],[],5,2,7,[],['gild'],https://twitter.com/JacobPlieth/status/948962522878660610,False,,0,,,,,,,,[],,,,
948960888475848704,948869866928463873,2018-01-04 22:24:41 IST,2018-01-04,22:24:41,+0530,873399943,jacobplieth,Jacob Plieth,,"Joshua Brody, Mount Sinai, reckons biggest bottleneck to CAR-T therapy is ICU bed availability ($5k/night), especially in flu season $GILD",en,[],[],[],1,4,14,[],['gild'],https://twitter.com/JacobPlieth/status/948960888475848704,False,,0,,,,,,,,[],,,,
948724439579025409,948724439579025409,2018-01-04 06:45:07 IST,2018-01-04,06:45:07,+0530,15568127,themotleyfool,The Motley Fool,,"Slowly but steadily, Big Pharma is chipping away at the Big C. If doing well by investing in those that do good appeals, check out $GILD $BMY $CELG $NVS $BAYRY  https://t.co/QdgKoGj0TI",en,[],['https://www.fool.com/investing/2017/12/30/3-biggest-breakthroughs-in-cancer-treatment-in-201.aspx'],[],0,5,23,[],"['gild', 'bmy', 'celg', 'nvs', 'bayry']",https://twitter.com/themotleyfool/status/948724439579025409,False,,0,,,,,,,,[],,,,
948641692105756674,948641692105756674,2018-01-04 01:16:18 IST,2018-01-04,01:16:18,+0530,529704495,damiangarde,Damian Garde,,"$GILD's market cap is smaller today than it was in December 2013, when Sovaldi won approval. like it never happened!  https://t.co/XJAUhnXU3Z",en,[],[],['https://pbs.twimg.com/media/DSpAbFvV4AAO8i2.jpg'],4,7,13,[],['gild'],https://twitter.com/damiangarde/status/948641692105756674,False,,1,https://pbs.twimg.com/media/DSpAbFvV4AAO8i2.jpg,,,,,,,[],,,,
948588554820648962,948588554820648962,2018-01-03 21:45:10 IST,2018-01-03,21:45:10,+0530,47678782,megtirrell,Meg Tirrell,,"$GILD also raising drug prices to start 2018, per Cowen  https://t.co/GDIQIKdlhK",en,[],[],['https://pbs.twimg.com/media/DSoQQx8WkAEtO9K.jpg'],3,7,10,[],['gild'],https://twitter.com/megtirrell/status/948588554820648962,False,,1,https://pbs.twimg.com/media/DSoQQx8WkAEtO9K.jpg,,,,,,,[],,,,
942066797531893760,942066797531893760,2017-12-16 21:50:01 IST,2017-12-16,21:50:01,+0530,576436187,carolineylchen,Caroline Chen,,"Here is part 2 on the difficulties of $GILD CAR-T reimbursement, for those of you who are health wonks interested in Medicare Part A   https://t.co/b7hkSdrzWr with @FayCortez",en,"[{'screen_name': 'faycortez', 'name': 'michelle fay cortez', 'id': '295746612'}]",['https://www.bloomberg.com/news/articles/2017-12-15/medicare-rigid-billing-system-leaves-gilead-cancer-drug-in-limbo'],[],2,8,15,[],['gild'],https://twitter.com/CarolineYLChen/status/942066797531893760,False,,0,,,,,,,,[],,,,
941299310808969216,941299310808969216,2017-12-14 19:00:18 IST,2017-12-14,19:00:18,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"This is a very good story, validates concerns of many investors about pace of CAR-T launch and complexities of reimbursement. $GILD $NVS $JUNO  https://t.co/7b4A4XKOrH",en,[],['https://twitter.com/ArmstrongDrew/status/941296364226478080'],[],8,34,54,[],"['gild', 'nvs', 'juno']",https://twitter.com/adamfeuerstein/status/941299310808969216,False,0,0,,,,,,,,[],,,,
941299190533120000,941299190533120000,2017-12-14 18:59:50 IST,2017-12-14,18:59:50,+0530,57124794,annaedney,Anna Edney,,Billing issues are keeping dying patients from getting Gilead's life-saving new cancer treatment  https://t.co/Ybvjk2EuSC by @FayCortez @CarolineYLChen @n_rausch21 $GILD,en,"[{'screen_name': 'faycortez', 'name': 'michelle fay cortez', 'id': '295746612'}, {'screen_name': 'carolineylchen', 'name': 'caroline chen', 'id': '576436187'}]",['https://www.bloomberg.com/news/articles/2017-12-14/cancer-patients-with-little-time-left-wait-for-gilead-s-new-drug'],[],1,6,6,[],['gild'],https://twitter.com/annaedney/status/941299190533120000,False,,0,,,,,,,,[],,,,
940632240748400640,940632240748400640,2017-12-12 22:49:36 IST,2017-12-12,22:49:36,+0530,873399943,jacobplieth,Jacob Plieth,,"How $JUNO missed the Transcend ""whisper numbers"", via @EPVantage #ASH17  https://t.co/pNrT26VHVr $NVS $GILD",en,"[{'screen_name': 'epvantage', 'name': 'vantage', 'id': '841963175729856512'}]",['http://epvantage.com/Universal/View.aspx?type=Story&id=753231&isEPVantage=yes'],[],6,9,27,['ash17'],"['juno', 'nvs', 'gild']",https://twitter.com/JacobPlieth/status/940632240748400640,False,,0,,,,,,,,[],,,,
940397734858842114,940397734858842114,2017-12-12 07:17:46 IST,2017-12-12,07:17:46,+0530,873399943,jacobplieth,Jacob Plieth,,"Sunil Agarwal $JUNO arguing that Transcend-NHL did not recruit ""less sick"" patients. That's been a major point of contention vs $KITE $GILD",en,[],[],[],3,5,9,[],"['juno', 'kite', 'gild']",https://twitter.com/JacobPlieth/status/940397734858842114,False,,0,,,,,,,,[],,,,
940310316411506688,940310316411506688,2017-12-12 01:30:24 IST,2017-12-12,01:30:24,+0530,873399943,jacobplieth,Jacob Plieth,,"I've tried to put $BLUE bb2121 data, being presented at #ASH17 now, into context. Via @EPVantage $JUNO $GILD $NVS  https://t.co/J4xbJOMAPj",en,"[{'screen_name': 'epvantage', 'name': 'vantage', 'id': '841963175729856512'}]",['http://epvantage.com/Universal/View.aspx?type=Story&id=752944&isEPVantage=yes'],[],4,20,41,['ash17'],"['blue', 'juno', 'gild', 'nvs']",https://twitter.com/JacobPlieth/status/940310316411506688,False,,0,,,,,,,,[],,,,
940224036101066752,940224036101066752,2017-12-11 19:47:33 IST,2017-12-11,19:47:33,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"The #ASH17 winners and losers: Hemophilia therapies show promise, $SYRS stumbles  https://t.co/R7o7WqwiIL via me! $GILD $BLUE $ONCE $JUNO $CELG etc. etc. etc....",en,[],['https://www.statnews.com/2017/12/11/hemophilia-biomarin-spark-syros-leukemia/'],[],0,6,12,['ash17'],"['syrs', 'gild', 'blue', 'once', 'juno', 'celg']",https://twitter.com/adamfeuerstein/status/940224036101066752,False,,0,,,,,,,,[],,,,
940212739590557696,940212739590557696,2017-12-11 19:02:40 IST,2017-12-11,19:02:40,+0530,873399943,jacobplieth,Jacob Plieth,,"Side by side, $GILD Zuma-1, $NVS Juliet, $JUNO Transcend (h/t @BursatilBiotech) #ASH17  https://t.co/Du7Sf3W5gr",en,"[{'screen_name': 'bursatilbiotech', 'name': 'bursatil biotech', 'id': '2926129144'}]",[],"['https://pbs.twimg.com/media/DQxOcjjUQAAMywh.jpg', 'https://pbs.twimg.com/media/DQxOddjV4AAF4ii.jpg', 'https://pbs.twimg.com/media/DQxOecFUMAI3I83.jpg']",1,14,26,['ash17'],"['gild', 'nvs', 'juno']",https://twitter.com/JacobPlieth/status/940212739590557696,False,,1,https://pbs.twimg.com/media/DQxOcjjUQAAMywh.jpg,,,,,,,[],,,,
939886670266163200,939886670266163200,2017-12-10 21:26:59 IST,2017-12-10,21:26:59,+0530,1081903728,drkomanduri,"Krishna Komanduri, MD, FASTCT",,Breaking: Neelapu et al Axi-Cel CAR-T Rx for refractory #lymphoma published in @NEJM. Proud to be part of this landmark study. $GILD #tcellrx #lymsm #bmtsm #ASH17   https://t.co/aq9IEJuYPR,en,"[{'screen_name': 'nejm', 'name': 'nejm', 'id': '25950355'}]",['http://www.nejm.org/doi/full/10.1056/NEJMoa1707447'],[],2,12,15,"['lymphoma', 'tcellrx', 'lymsm', 'bmtsm', 'ash17']",['gild'],https://twitter.com/drkomanduri/status/939886670266163200,False,,0,,,,,,,,[],,,,
939884563576303616,939880286065700864,2017-12-10 21:18:36 IST,2017-12-10,21:18:36,+0530,873399943,jacobplieth,Jacob Plieth,,S Neelapu: only 8% (!) of Zuma-1 subjects needed IVIG $GILD #ASH17,en,[],[],[],1,4,9,['ash17'],['gild'],https://twitter.com/JacobPlieth/status/939884563576303616,False,,0,,,,,,,,[],,,,
939883811453751297,939880286065700864,2017-12-10 21:15:37 IST,2017-12-10,21:15:37,+0530,873399943,jacobplieth,Jacob Plieth,,S Neelapu Zuma-1 KM curves $GILD #ASH17  https://t.co/XDi5MzQgr1,in,[],[],['https://pbs.twimg.com/media/DQsjTqEWAAArbTV.jpg'],1,5,6,['ash17'],['gild'],https://twitter.com/JacobPlieth/status/939883811453751297,False,,1,https://pbs.twimg.com/media/DQsjTqEWAAArbTV.jpg,,,,,,,[],,,,
939883125072687106,939880286065700864,2017-12-10 21:12:53 IST,2017-12-10,21:12:53,+0530,873399943,jacobplieth,Jacob Plieth,,S Neelapu: some Zuma-1 patients converted from PD/PR to CR up to 15 mths after single Yescarta treatment $GILD #ASH17,en,[],[],[],2,7,10,['ash17'],['gild'],https://twitter.com/JacobPlieth/status/939883125072687106,False,,0,,,,,,,,[],,,,
939880640085979136,939880640085979136,2017-12-10 21:03:01 IST,2017-12-10,21:03:01,+0530,102754598,johncendpts,John Carroll,,-- #ASH17: How does Novartis‚Äô Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead? $NVS $GILD   https://t.co/5PEZQIVVHr,en,[],['https://endpts.com/ash17-how-does-novartis-kymriah-dlbcl-data-stack-up-heading-straight-to-a-car-t-showdown-with-gilead/'],[],0,7,11,['ash17'],"['nvs', 'gild']",https://twitter.com/JohnCendpts/status/939880640085979136,False,,0,,,,,,,,[],,,,
939880467356180480,939880467356180480,2017-12-10 21:02:20 IST,2017-12-10,21:02:20,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"CAR-T therapies prove durable, stopping cancer for months ‚Äî even years ‚Äî in some patients  https://t.co/sd0ygKWZyQ The latest from #ASH17 $GILD $NVS $BLUE",en,[],['https://www.statnews.com/2017/12/10/car-t-cancer-ash-durable/'],[],2,48,61,['ash17'],"['gild', 'nvs', 'blue']",https://twitter.com/adamfeuerstein/status/939880467356180480,False,,0,,,,,,,,[],,,,
939880286065700864,939880286065700864,2017-12-10 21:01:36 IST,2017-12-10,21:01:36,+0530,873399943,jacobplieth,Jacob Plieth,,"$GILD Zuma-1 lymphoma study update, via S Neelapu #ASH17 $NVS $JUNO  https://t.co/YkysEPDfw0",en,[],[],"['https://pbs.twimg.com/media/DQsgGhXWkAAZVO0.jpg', 'https://pbs.twimg.com/media/DQsgGhkXcAA-Jsp.jpg', 'https://pbs.twimg.com/media/DQsgGhwW4AAISAv.jpg', 'https://pbs.twimg.com/media/DQsgGhvX0AASLc_.jpg']",1,16,29,['ash17'],"['gild', 'nvs', 'juno']",https://twitter.com/JacobPlieth/status/939880286065700864,False,,1,https://pbs.twimg.com/media/DQsgGhXWkAAZVO0.jpg,,,,,,,[],,,,
939880007014416386,939880007014416386,2017-12-10 21:00:30 IST,2017-12-10,21:00:30,+0530,873399943,jacobplieth,Jacob Plieth,,"$BLUE bb2121 BCMA CAR update, via J Kochenderfer #ASH17 $JUNO $GILD $NVS  https://t.co/leCdBIJ1LP",en,[],[],"['https://pbs.twimg.com/media/DQsfy7QX4AAUUeQ.jpg', 'https://pbs.twimg.com/media/DQsfy7FWkAEEYru.jpg', 'https://pbs.twimg.com/media/DQsf1VgW0AA3NDj.jpg']",3,20,39,['ash17'],"['blue', 'juno', 'gild', 'nvs']",https://twitter.com/JacobPlieth/status/939880007014416386,False,,1,https://pbs.twimg.com/media/DQsfy7QX4AAUUeQ.jpg,,,,,,,[],,,,
939864889908178944,939864889908178944,2017-12-10 20:00:26 IST,2017-12-10,20:00:26,+0530,873399943,jacobplieth,Jacob Plieth,,"#ASH17 CAR-T press conference starting at 10:30am ET. Stay tuned for $GILD Zuma-1, $NVS Juliet and $BLUE bb2121 updates",en,[],[],[],0,5,20,['ash17'],"['gild', 'nvs', 'blue']",https://twitter.com/JacobPlieth/status/939864889908178944,False,,0,,,,,,,,[],,,,
939829476615163904,939829476615163904,2017-12-10 17:39:43 IST,2017-12-10,17:39:43,+0530,873399943,jacobplieth,Jacob Plieth,,"JCARH125, $JUNO anti-BCMA CAR, to start clinical trials in Q1 2018 #ASH17 $BLUE $NVS $GILD  https://t.co/qQlna1RizN",en,[],[],"['https://pbs.twimg.com/media/DQrx5pYWkAEbABN.jpg', 'https://pbs.twimg.com/media/DQrx6bqWAAABjUt.jpg']",1,8,27,['ash17'],"['juno', 'blue', 'nvs', 'gild']",https://twitter.com/JacobPlieth/status/939829476615163904,False,,1,https://pbs.twimg.com/media/DQrx5pYWkAEbABN.jpg,,,,,,,[],,,,
939244042935853057,939244042935853057,2017-12-09 02:53:24 IST,2017-12-09,02:53:24,+0530,873399943,jacobplieth,Jacob Plieth,,R Brentjens: BCMA might very well be the next CAR-T target to be approved after CD19 $BLUE $JUNO $NVS $GILD #ASH17,en,[],[],[],5,11,14,['ash17'],"['blue', 'juno', 'nvs', 'gild']",https://twitter.com/JacobPlieth/status/939244042935853057,False,,0,,,,,,,,[],,,,
939096401845374977,938922214761680896,2017-12-08 17:06:44 IST,2017-12-08,17:06:44,+0530,873399943,jacobplieth,Jacob Plieth,,Retweeting this re $GILD purchase of Cell Design Labs  https://t.co/6aRRujW0lR,en,[],['https://twitter.com/jacobplieth/status/721440477283803136'],[],0,4,9,[],['gild'],https://twitter.com/JacobPlieth/status/939096401845374977,False,https://twitter.com/jacobplieth/status/721440477283803136,0,,,,,,,,[],,,,
939087902931410944,939087902931410944,2017-12-08 16:32:58 IST,2017-12-08,16:32:58,+0530,102754598,johncendpts,John Carroll,,$GILD is buying a CAR-T 2.0 biotech in a $567M deal. Who's next?  https://t.co/8rDZsAQSe1,en,[],['https://endpts.com/gilead-swoops-in-with-567m-deal-to-buy-car-t-2-0-player-cell-design-labs/'],[],2,9,15,[],['gild'],https://twitter.com/JohnCendpts/status/939087902931410944,False,,0,,,,,,,,[],,,,
938930746177261574,938922214761680896,2017-12-08 06:08:29 IST,2017-12-08,06:08:29,+0530,873399943,jacobplieth,Jacob Plieth,,"@DewDiligence If what you say is true, and it sounds like it is, then this is a bushleague PR from $GILD",en,[],[],[],1,0,8,[],['gild'],https://twitter.com/JacobPlieth/status/938930746177261574,False,,0,,,,,,,,"[{'screen_name': 'DewDiligence', 'name': 'Roy Friedman', 'id': '442298073'}]",,,,
938922214761680896,938922214761680896,2017-12-08 05:34:34 IST,2017-12-08,05:34:34,+0530,873399943,jacobplieth,Jacob Plieth,,Am I understanding this correctly? The $KITE Cell Design Labs stake wasn‚Äôt included in $GILD‚Äôs acquisition of Kite?,en,[],[],[],2,1,6,[],['kite'],https://twitter.com/JacobPlieth/status/938922214761680896,False,,0,,,,,,,,[],,,,
938898310487838721,938898310487838721,2017-12-08 03:59:35 IST,2017-12-08,03:59:35,+0530,102754598,johncendpts,John Carroll,,#cooltech! Gilead swoops in with $567M deal to buy CAR-T 2.0 player Cell Design Labs $GILD $NVS  https://t.co/8rDZsAQSe1,en,[],['https://endpts.com/gilead-swoops-in-with-567m-deal-to-buy-car-t-2-0-player-cell-design-labs/'],[],3,12,32,['cooltech'],"['gild', 'nvs']",https://twitter.com/JohnCendpts/status/938898310487838721,False,,0,,,,,,,,[],,,,
938892531475021825,938892531475021825,2017-12-08 03:36:37 IST,2017-12-08,03:36:37,+0530,47678782,megtirrell,Meg Tirrell,,"$GILD &amp; $KITE to acquire Cell Design Labs for $175m upfront, $322m in potential milestones, gaining two cool-sounding technologies for CAR-T: one for dual antigen recognition, and another for an ""on switch"" to modulate CAR-T activity using small molecules  https://t.co/Ql1es5ywGS",en,[],['http://www.businesswire.com/news/home/20171207006250/en/'],[],8,46,67,[],"['gild', 'kite']",https://twitter.com/megtirrell/status/938892531475021825,False,,0,,,,,,,,[],,,,
938891251776188418,938891251776188418,2017-12-08 03:31:32 IST,2017-12-08,03:31:32,+0530,576436187,carolineylchen,Caroline Chen,,$GILD confirms buying Cell Design Labs for up to $567 million for CAR-T technology.,en,[],[],[],2,11,18,[],['gild'],https://twitter.com/CarolineYLChen/status/938891251776188418,False,,0,,,,,,,,[],,,,
937471623531323393,937471623531323393,2017-12-04 05:30:27 IST,2017-12-04,05:30:27,+0530,274233761,bradloncar,Brad Loncar,,Also bummed that $GILD/Kite don't seem to be having an event. I guess it's the reality that when you become a bigger company it doesn't matter as much.,en,[],[],[],1,2,10,[],['gild'],https://twitter.com/bradloncar/status/937471623531323393,False,,0,,,,,,,,[],,,,
936590775789506560,936590775789506560,2017-12-01 19:10:16 IST,2017-12-01,19:10:16,+0530,23094787,arleneweintraub,Arlene Weintraub,,Gene Therapy Is Booming But How Will We Manage The Costs? Interesting debate at #ForbesHealth Summit  https://t.co/DxekTj2Oyn @forbeshealth $GILD $ONCE $BLUE  https://t.co/C6gH3SybA4,en,"[{'screen_name': 'forbeshealth', 'name': 'forbes health', 'id': '47443693'}]",['http://ow.ly/McKm30gWG5S'],['https://pbs.twimg.com/media/DP9wWJjXUAEV5E4.jpg'],3,9,9,['forbeshealth'],"['gild', 'once', 'blue']",https://twitter.com/arleneweintraub/status/936590775789506560,False,,1,https://pbs.twimg.com/media/DP9wWJjXUAEV5E4.jpg,,,,,,,[],,,,
936231296673681409,936231296673681409,2017-11-30 19:21:50 IST,2017-11-30,19:21:50,+0530,47678782,megtirrell,Meg Tirrell,,"""Take Harvoni. I thnk $GILD was in its rights to charge $80k for that drug,"" Dana-Farber CEO Laurie Glimcher says. Meanwhile, I imagine @peterbachmd's head is quietly exploding next to her on stage. #ForbesHealth",en,"[{'screen_name': 'peterbachmd', 'name': 'peter b. bach, md', 'id': '277191527'}]",[],[],4,8,22,['forbeshealth'],['gild'],https://twitter.com/megtirrell/status/936231296673681409,False,,0,,,,,,,,[],,,,
935957450481717255,935957450481717255,2017-11-30 01:13:40 IST,2017-11-30,01:13:40,+0530,274233761,bradloncar,Brad Loncar,,"Given how the tax bill is in the news, Credit Suisse has a nice report showing for large companies what percent of their cash is overseas. Some biopharma names:  $JNJ 96% $AMGN 94% $GILD 85% $PFE 90% $MRK 85% $CELG 77% $BIIB 70%",en,[],[],[],11,74,115,[],"['jnj', 'amgn', 'gild', 'pfe', 'mrk', 'celg', 'biib']",https://twitter.com/bradloncar/status/935957450481717255,False,,0,,,,,,,,[],,,,
935922199256481792,935922199256481792,2017-11-29 22:53:35 IST,2017-11-29,22:53:35,+0530,20119344,greenbackd,Tobias Carlisle,,This is fun: Investor Ryan Boselo is tracking the free Acquirer's Multiple Large Cap Screener ( https://t.co/Yd2n66uh2L) on @SeekingAlpha $ABX $ALK $AUO $DAL $ESRX $FCAU $GILD $HUM  https://t.co/rckEyrEgpg,en,"[{'screen_name': 'seekingalpha', 'name': 'seeking alpha', 'id': '23059499'}]","['https://acquirersmultiple.com/screener/large-cap/', 'https://seekingalpha.com/article/4128359-acquirers-portfolio-large-cap']",[],1,0,9,[],"['abx', 'alk', 'auo', 'dal', 'esrx', 'fcau', 'gild', 'hum']",https://twitter.com/Greenbackd/status/935922199256481792,False,,0,,,,,,,,[],,,,
935176403162681345,935176403162681345,2017-11-27 21:30:03 IST,2017-11-27,21:30:03,+0530,20119344,greenbackd,Tobias Carlisle,,Debating $GILD $DAL $LUV and $UNP with @PrestonPysh @stig_brodersen and @harirama on The Investor's Podcast.  https://t.co/07XbtKrszw,en,"[{'screen_name': 'prestonpysh', 'name': 'preston pysh', 'id': '538399586'}, {'screen_name': 'stig_brodersen', 'name': 'stig t. brodersen', 'id': '1493298541'}, {'screen_name': 'harirama', 'name': 'hari ramachandra', 'id': '14983892'}]",['https://twitter.com/acquirersx/status/935070873081602049'],[],3,8,24,[],"['gild', 'dal', 'luv', 'unp']",https://twitter.com/Greenbackd/status/935176403162681345,False,https://twitter.com/acquirersx/status/935070873081602049,0,,,,,,,,[],,,,
934808987740069888,934808987740069888,2017-11-26 21:10:05 IST,2017-11-26,21:10:05,+0530,250758475,jboorman,Jon Boorman,,"$GILD wrestling with previous breakout area, 40-wk MA, barely intact.  https://t.co/wBkIBrd6Xz",en,[],[],['https://pbs.twimg.com/media/DPkb0eSUIAImkuB.jpg'],2,1,11,[],['gild'],https://twitter.com/JBoorman/status/934808987740069888,False,,1,https://pbs.twimg.com/media/DPkb0eSUIAImkuB.jpg,,,,,,,[],,,,
933511706915024898,933511706915024898,2017-11-23 07:15:09 IST,2017-11-23,07:15:09,+0530,15568127,themotleyfool,The Motley Fool,,"When a biopharmaceutical acts like a blockbuster franchise has no future, that can be a good thing. $GILD  https://t.co/CcQyuWQH3S",en,[],['https://www.fool.com/investing/2017/11/21/the-1-thing-missing-from-gilead-sciences-2018-prio.aspx'],[],1,4,11,[],['gild'],https://twitter.com/themotleyfool/status/933511706915024898,False,,0,,,,,,,,[],,,,
933079501361307651,933079501361307651,2017-11-22 02:37:43 IST,2017-11-22,02:37:43,+0530,102754598,johncendpts,John Carroll,,"With billions riding on their success, $GSK bags quick OK for its two-drug HIV combo Juluca $GILD  https://t.co/sg5OAlzZRC",en,[],['https://endpts.com/with-billions-riding-on-their-success-gsk-bags-quick-ok-for-its-two-drug-hiv-combo-juluca/'],[],0,7,7,[],"['gsk', 'gild']",https://twitter.com/JohnCendpts/status/933079501361307651,False,,0,,,,,,,,[],,,,
932344694188707843,932344694188707843,2017-11-20 01:57:51 IST,2017-11-20,01:57:51,+0530,250758475,jboorman,Jon Boorman,,"$GILD big level for this, all the way back to previous swing low and 40-week MA.  https://t.co/1oUIGBt7fd",en,[],[],['https://pbs.twimg.com/media/DPBajq3XkAARGOK.jpg'],4,2,17,[],['gild'],https://twitter.com/JBoorman/status/932344694188707843,False,,1,https://pbs.twimg.com/media/DPBajq3XkAARGOK.jpg,,,,,,,[],,,,
